Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, the Hooked C project by Caven, Madeleine
                                                                          
University of Dundee
MASTER OF SCIENCE
Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People






Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 20. Apr. 2021
Hepatitis C Diagnosis and Treatment, Impact on Engagement 
and Behaviour of People Who Inject Drugs,      
the Hooked C project 
Madeleine Caven 
Thesis presented for the degree of 
Master of Science (by Research) in Medicine 
University of Dundee 
October 2020 
2 
Table of Contents 
Table of Contents   2 
List of Figures   7 
List of Tables   8 
Acknowledgements   9 
Signed Declarations   10 
Contributions   11 
Abstract   12 
Abbreviations   14 
1. Introduction  16 
1.1 Introduction to Hepatitis C virus infection              16 
1.2 History of Hepatitis C treatment             17 
1.3 Barriers and stigma relating to treatment access   19 
1.4 HCV diagnosis and injecting behaviours       20 
1.5 Healthcare utilisation of people who inject drugs  21 
1.6 Drug related deaths crisis         22 
1.7 Justification for study                 23 
1.8 Research questions and hypotheses                25 
3 
 
2. Impact of Hepatitis C treatment on behavioural change in relation                 27     
to drug use in people who inject drugs: a systematic review 
 
2.1 Abstract                                                                                                          27 
2.2 Objectives                                                                                                      28 
2.3 Methodology                                                                                                 29 
2.3.1 Population                                                                               29 
2.3.2 Intervention                                                                            30 
2.3.3 Comparison                                                                             30 
2.3.4 Outcomes                                                                                30 
2.3.5 Study designs                                                                          32 
2.3.6 Search strategy                                                                       32 
2.3.7 Study selection                                                                       33 
2.3.8 Data extraction and synthesis                                             35 
2.3.9 Quality appraisal                                                                    35 
2.4 Results                                                                                                             36 
2.4.1 Search results                                                                          36 
2.4.2 Characteristics of selected studies                                      36 
2.4.3 Risk of bias in individual studies                                          41 
2.4.4 Results of individual studies                                                 44 
2.4.4.1 Impact of treatment on past month injecting 
drug use                                                                   44 
4 
 
2.4.4.2 Impact of treatment on injecting frequency     45 
2.4.4.3 Impact of treatment on needle and syringe    
borrowing                                                                46 
2.4.4.4 Impact of treatment on injecting equipment 
sharing                                                                     46 
2.5 Discussion                                                                                                       47 
2.5.1 Summary of evidence                                                            47 
2.5.2 Limitations of review                                                             49 
2.5.3 Conclusions                                                                             50 
 
3. Hepatitis C Diagnosis and Treatment, Impact on Engagement                           51    
and Behaviour of People Who Inject Drugs, a service evaluation,                             
the Hooked C project 
 
3.1 Abstract                                                                                                          52 
3.2 Objectives                                                                                                      53 
3.3 Methodology                                                                                                 55 
3.3.1 Approvals                                                                                55 
3.3.2 Study design                                                                           55 
3.3.3 Data sources and data linkage                                            55 
3.3.4 Identification of selected cohort                                        56 
3.3.5 Outcome variables                                                                58 
5 
 
3.3.5.1 All-cause mortality and drug related death    58 
3.3.6 Predictor variables                                                               58 
3.3.6.1 Treatment engagement                                     58     
3.3.6.2 Opioid substitution therapy (OST)                   59 
3.3.6.3 Cirrhosis                                                                59 
3.3.6.4 SVR                                                                         59 
3.3.7 Statistical analysis                                                                60 
3.3.7.1 Assumptions for binary logistic regressions   60 
3.3.7.2 Coding of categorical predictors                       61 
3.4 Results                                                                                                           63 
3.4.1 Analysis 1- PCR Positive vs Negative                                 63                 
3.4.2 Analysis 2- PCR Positive treatment engagers vs PCR     
Positive treatment non- engagers                                      71 
3.4.3 Analysis 3- Interferon treated vs DAA treated                 76 
3.5 Discussion                                                                                                      80 
3.5.1 Limitations                                                                              83 
3.5.2 Strengths                                                                                 84 
3.5.3 Conclusions                                                                             85 
 
4. General Discussion                                                                                                       86 
 
4.1 Directions for future research                                                                    87 
6 
4.2 Implementation  89 
5. References  90 
6. Appendices  101 
6.1 Appendix A- Copy of systematic review publication    102 
6.2 Appendix B- Copy of Hooked C project publication         110 
6.3 Appendix C- Copy of Caldicott Guardian approval    119 
7 
List of Figures 
Figure 1. Search Strategy  34 
Figure 2. Selection of PCR Positive cases and PCR Negative controls based  65 
on inclusion/ exclusion criteria.  
Figure 3. Kaplan Meier survival curve for time from first antibody positive test      66 
to all-cause mortality comparing PCR Positive cases and PCR Negative controls 
Figure 4. Kaplan Meier survival curve for time from first antibody positive test      67   
to drug related death comparing PCR Positive cases and PCR Negative controls 
Figure 5. Selection of treatment engaging/interferon treated cases       73 
and treatment non- engaging/direct acting antiviral treated controls based on 
inclusion/exclusion criteria 
Figure 6. Kaplan Meier survival curve for time from first antibody positive test      74  
to all-cause mortality comparing treatment engaging cases and treatment non-
engaging controls 
Figure 7. Kaplan Meier survival curve for time from first antibody positive test      75 
to drug related death comparing treatment engaging cases and treatment non-
engaging controls 
Figure 8. Kaplan Meier survival curve for time from treatment commencement    78 
to all-cause mortality comparing interferon treated cases and direct acting     
antiviral agent treated controls  
Figure 9. Kaplan Meier survival curve for time from treatment commencement    79   
to drug related death comparing interferon treated cases and direct acting    
antiviral agent treated controls  
8 
List of Tables 
Table 1. Inclusion Criteria 31 
Table 2. Exclusion Criteria     31 
Table 3. Keyword search terms utilised in search strategy, grouped by search        33 
topic 
Table 4. Summary of Study Characteristics    38 
Table 5. Quality appraisal ratings for each included study    42 
Table 6. Inclusion/Exclusion Criteria    57       
Table 7. Baseline characteristics of PCR Positive cases and PCR Negative       68 
controls (Analysis 1); Treatment Engaging cases and Treatment Non- Engaging 
controls (Analysis 2); and Interferon treated cases and DAA treated controls 
(Analysis 3) 
Table 8. Summary of logistic regression analyses for control variables (age,       69 
sex, SVR, OST, and cirrhosis), PCR status (Analysis 1), Treatment Engagement 
(Analysis 2), and Treatment Regimen (Analysis 3) predicting all-cause mortality 
Table 9. Summary of logistic regression analyses for control variables (age,       70 
sex, SVR, OST, and cirrhosis), PCR status (Analysis 1), Treatment Engagement 
(Analysis 2), and Treatment Regimen (Analysis 3) predicting drug related death 
9 
Acknowledgements 
          First and foremost, I would like to sincerely thank Professor John Dillon for 
offering me this opportunity, and for his committed and insightful supervision 
throughout this project. My gratitude also goes to my second supervisor, Dr Emma 
Fletcher, for her guidance, support, and encouragement.  
          I would also like to thank every member of the Gut Group for sharing their wealth 
of knowledge and experience, showing me great kindness and support. I would 
especially like to thank Dr Emma Robinson, Miss Amy Malaguti, Mrs Shirley Cleary, Mrs 
Linda Johnston, and Dr Iain Macpherson. 
          I would like to thank Mrs Ann Eriksen and NHS Tayside Sexual Health & Blood 
Borne Virus Managed Care Network (MCN) for funding this project. I am also indebted 
to the Gut Group for covering my tuition fees. 
         Finally, I would like to thank my family and friends for their ever-present and 
valued support.   
10 
Signed Declarations 
         I, Madeleine Caven, hereby certify that I am the author of this thesis, that the 
work of which it is a record of has been conducted by me, that all references cited have 
been consulted by me, and that it has not previously been accepted for a Higher 
Degree.  
13/05/20 
         Signature of Candidate   Date 
I hereby certify that the candidate has fulfilled the Conditions of Ordinance and 
regulation for the degree of Master of Science (by Research) in the University of 
Dundee. 
13/05/20 
         Signature of Supervisor  Date 
11 
Contributions 
         Madeleine Caven, Amy Malaguti, Emma Robinson, Emma Fletcher, Ann Eriksen, 
and John Dillon contributed to the research reported in this thesis. Madeleine Caven 
undertook and contributed to all aspects and stages of the research. Amy Malaguti and 
Emma Robinson participated in the quality assessment stage of the systematic review. 
Ann Eriksen provided feedback on drafted publications. John Dillon conceived the idea 
of the Hooked C project. Emma Fletcher and John Dillon provided supervision, 
assistance and feedback throughout the project.  
12 
Abstract 
         Hepatitis C (HCV) virus affects around 71 million people globally, with people who 
inject drugs (PWID) the most at-risk population for acquisition of the virus. There is 
emerging evidence that HCV treatment engagement is associated with change in drug 
behaviours and reduced risk of mortality among PWID. A systematic review was 
conducted to determine the impact of HCV treatment on injecting risk behaviours in 
PWID. Following this, a series of retrospective case control studies investigated 
whether HCV diagnosis and treatment engagement reduces risk of all-cause mortality 
and drug related death among PWID, and whether any effect is dependent on 
treatment regimen and intensity of engagement with staff. 
         Comparison and synthesis of results of the systematic review was challenging due 
to heterogeneity between studies. However, results suggested that it is likely that 
engaging in HCV treatment has a positive impact upon patients’ injecting drug use and 
injection equipment sharing behaviour. Through the case control studies, it was found 
that HCV diagnosis does not impact upon mortality outcomes of PWID. However, HCV 
treatment engagement is significantly protective against all-cause mortality and drug 
related death, with this effect independent of treatment regimen and intensity of 
engagement with staff. 
          These findings provide strong evidence of the importance of universal HCV 
testing and treatment accessibility for PWID, reducing their risk of mortality beyond 
liver related outcomes. It is vital that efforts are made to actively minimise barriers and 
stigma relating to treatment access for PWID to facilitate HCV diagnosis and linkage to 
care. Future research should focus upon understanding the key barriers and facilitators 
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to engagement to aid the development of interventions that increase the reach, 
accessibility and effectiveness of HCV care, improving treatment pathways in pursuit of 
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Introduction to Hepatitis C virus infection 
 
          Chronic Hepatitis C (HCV) infection is a blood borne virus which affects around 71 
million people globally (World Health Organisation, 2017; Blach et al., 2017). 
Prevalence of the virus dramatically varies by country, ranging from less than 1% in 
certain Western countries, to over 10% in some African and Middle Eastern nations 
(Hajarizadeh, Grebely, & Dore, 2013). The most common method of transmission is 
through injecting drug use behaviour, such as the sharing of needles, syringes and 
other ancillary injecting equipment. Other less common methods of transmission 
include transfusion of infected blood products, sexual transmission and vertical 
transmission from HCV positive mothers to babies. In the case of transfusion of 
infected blood products, this method of transmission was previously more relevant 
before mandatory blood screening tests became practice, and in less developed 
healthcare systems, where needle reuse is common. People who inject drugs (PWID) 
are the most at- risk population for acquisition of the virus, with an estimated 39.2% of 
PWID currently living with HCV infection worldwide (Grebely et al., 2019). HCV 
infection is a major cause of morbidity and mortality among this population, through 
the development of both hepatic diseases, e.g. liver cirrhosis and hepatocellular 
carcinoma, and extra-hepatic diseases (Stanaway et al., 2016). Extra- hepatic 
manifestations of HCV can affect the kidneys, immune system, eyes, thyroid, and the 
nervous system, and are reported in nearly 75% of patients (Cacoub, Gragnani, 
Comarmond, & Zignego, 2014). Therefore, HCV infection can be described as a 
multifaceted systematic disease, with complex health consequences. HCV has a long 
clinical course, with around 20- 30% of patients developing cirrhosis within 20 years of 




History of Hepatitis C treatment 
 
          The objective of Hepatitis C treatment is full eradication of the virus, which is 
paramount for the prevention of disease progression, and onward viral transmission. 
Crucially, the primary goal of treatment is for a patient to achieve a sustained 
virological response (SVR), defined as undetectable HCV RNA either 12 or 24 weeks 
post treatment completion (European Association for the Study of the Liver, 2018). 
Initial treatment options beginning in the 1990s were based upon interferon alpha 
based therapies, injected subcutaneously, with treatment regimens involving 24 or 48 
week courses, depending on the genotype of the virus (Powell et al., 1997). Cure rates 
using interferon alpha based therapy were very poor, with fewer than 10% of patients 
successfully clearing their virus (Carithers, & Emerson, 1997). However, the addition of 
ribavirin (RBV) to treatment regimens significantly improved treatment outcomes, with 
SVR rates rising to around 30% (McHutchison et al., 1998).  
 
         Interferon based treatment again progressed with the development of pegylated 
forms of interferon alpha, eliciting higher SVR rates, and in combination with RBV, was 
the standard of care for patients until around 2011 (Foster, 2010). Despite improved 
outcomes, many patients were not eligible for treatment due to numerous 
contraindications. For example, due to the neuropsychiatric effects of interferon, 
treatment was not appropriate for patients with unstable psychiatric conditions. 
Moreover, interferon based treatment regimens evoked multiple arduous side effects, 
such as flu- like symptoms, fatigue, lethargy, changes in mood, skin reactions, and 
sleep disturbance, resulting in inadequate tolerability, and poor treatment adherence 
and completion rates (Fried, 2002). Consequently, many patients declined therapy due 




         HCV treatment was greatly advanced by the revolutionary development of 
multiple direct acting antivirals (DAAs), which target distinct stages within the life cycle 
of the HCV virus (Dore, 2012). Originally offered in conjunction with interferon alpha 
and RBV, interferon free regimens quickly became available for the treatment of HCV. 
DAA based therapies provide simplified treatment regimens, are oral based, of short 
duration (around 8- 16 weeks), with SVR rates in excess of 95% (Falade- Nwulia et al., 
2017). In contrast to interferon based treatment, DAA based therapies have minimal 
side effects, with vast improvements in tolerability. This has facilitated the treatment 
of an extensive group patients who were previously ineligible for therapy (Younossi et 
al., 2015).  
 
          The efficacy of pan-genotypic DAAs provides an excellent opportunity to scale up 
HCV diagnosis and treatment, with the ultimate aim of achieving the World Health 
Organisation target of global HCV elimination by 2030 (Asselah, Marcellin, & Schinazi, 
2018; World Health Organisation, 2016). Research has supported the treatment of 
Hepatitis C in people who inject drugs , demonstrating successful adherence to 
treatment and favourable SVR rates (Hajarizadeh et al., 2018; Schulkind et al., 2019). 
This highlights the feasibility and effectiveness of scaling up treatment services to 
reduce the prevalence of the disease, using “treatment as prevention” (TasP) models 
of elimination (Aspinall et al., 2013; Fraser et al., 2018). TasP models of elimination 
focus on treating PWID for HCV as they are the most at-risk population for acquiring 
the virus. Therefore, HCV elimination could be achieved by treating those at risk of 
continuous HCV transmission (Hellard, Doyle, Sacks- Davis, Thompson, & McBryde, 






Barriers and stigma relating to treatment access 
 
          Despite the incidence of HCV related liver disease being on the rise, and research 
supporting the treatment of people who inject drugs; testing, diagnosis, and treatment 
rates of HCV infection among PWID have found to be inadequate in some settings 
(Socías et al., 2019; Thrift, El-Serag, & Kanwal, 2017; Wiessing et al., 2014). Barriers to 
testing and treatment are complex, and operate at various levels. For instance, at a 
systemic level, modelling of HCV testing and treatment cascades have shown 
inadequate diagnosis rates, and linkage to care (Ramers, Liu, & Frenette, 2019). Other 
systemic barriers may include geographic limitations to HCV specialists, lack of 
consensus around testing and treatment guidelines, lack of knowledge and awareness 
about HCV among practitioners, disease severity restrictions, and in the case of 
countries such as the USA, lack of insurance coverage and sobriety restrictions 
(Grebely, Oser, Taylor, & Dore, 2013).  
 
          At a treatment provider level, reluctance and concern around the treatment of 
people who are actively injecting drugs are considerable barriers to treatment 
accessibility for this population. For instance, a survey of over one hundred HCV 
treatment prescribing clinicians at the Liver Meeting in 2014 found that only 15% 
would be willing to treat active injectors with DAA based therapy (Asher et al., 2016). 
Concerns around treating people who inject drugs for HCV include: ongoing risk 
behaviour, such as ongoing drug use and the sharing of injecting paraphernalia; risk of 
reinfection; and poor treatment adherence (Grebely & Tyndall, 2011). Moreover, the 
perception that HCV treatment prescribing is restricted to specialist physicians remains 
prevalent in the DAA era, with many failing to recognise the success of implementing 
primary care and outreach based treatment pathways of care (Johnson, Aluzaite, Taat, 
& Schultz, 2019; Tait et al., 2017; Radley, Tait, & Dillon, 2017).  
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          Lastly, various barriers to HCV care are faced by those living with the infection in 
relation to patients’ own perceptions of treatment. Studies have shown that poor 
knowledge and awareness of HCV is associated with lower likelihood of treatment 
uptake and willingness to engage with treatment services (Treloar, Hull, Dore, & 
Grebely, 2012). For example, the absence of noticeable symptoms of HCV results in 
lack of motivation of individuals to undergo treatment, due to inaccurate perceptions 
around disease progression and prognosis (Lin et al., 2017). Furthermore, patients’ 
reluctance to undergo treatment may stem from their lack of knowledge around the 
side effect free nature and high cure rates associated with DAA based treatment, in 
comparison to the old interferon based regimens (Valerio et al., 2018; Jost et al., 2019). 
Various sociodemographic factors such as unstable housing, unemployment, mental 
health problems, ongoing drug use, stigma, and incarceration all affect a patient’s 
ability to access HCV care (Grebely, & Tyndall, 2011; Falade- Nwulia et al., 2019).  
 
HCV diagnosis and injecting behaviours  
 
        In spite of these barriers to treatment, there is a suggestion that the benefits of 
engaging with HCV care stretch beyond liver morbidity outcomes. Studies report the 
positive impact of HCV status notification on reduction in drug use among PWID. For 
instance, Aspinall et al. (2014) observed that receiving a HCV diagnosis was associated 
with a slight reduction in injecting frequency, but not injecting equipment borrowing, 
in a cohort of Australian PWID. Bruneau et al. (2014) found a sustained trend in 
reduction of injecting drug use among PWID who had been notified of their HCV 
positive status. Conversely, PWID who were seronegative, and notified of their status, 
after testing displayed no change in such behaviour over time. However, subsequent 
research has contested these findings, with a study using data from multiple countries,  
by Spelman et al. (2015) finding no difference in post notification injecting behaviours 
when comparing PWID who received a positive test result to those who tested HCV 
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negative, highlighting the need for greater communication by healthcare professionals 
of the importance of reducing injecting risk behaviours.  
 
Healthcare utilisation of people who inject drugs  
 
          Research has highlighted the poor health outcomes and increased mortality rates 
of people who inject drugs in comparison to the general population, including high 
rates of drug related deaths, HIV related deaths, increased risk of cancers, and various 
cardiovascular, liver and respiratory conditions (Mathers et al., 2013; Alridge et al., 
2018; Degenhardt et al., 2011). Yet, studies have also identified diversified barriers to 
PWID utilising healthcare services. As discussed previously, healthcare professionals 
may harbour prejudiced attitudes towards treating PWID, believing them to be drug 
seeking, and exhibiting problematic behaviour during interactions (Van Boekel, 
Brouwers, Van Weeghel, & Garretsen, 2013).  As a result of these perceptions, patients 
report delays in seeking treatment due to fear of stigmatisation, and apprehension 
around insufficient opioid substitution therapy and pain control when hospitalised 
(Summers, Hellman, MacLean, Rees, & Wilkes, 2018).  Consequently, this may lead to 
postponement of symptom presentation. This is evidenced by a recent meta-analysis 
investigating frequency of healthcare utilisation reported in observational studies of 
PWID, which found that PWID attended accident and emergency departments and are 
admitted to hospital on average 4.8 and 7.1 times more often, respectively, than the 







Drug related deaths crisis  
 
          The dominant causes of mortality among people who inject drugs are all strongly 
associated with active drug use behaviour, such as trauma and suicide, with the most 
common cause of mortality being accidental overdose (Degenhardt et al., 2011). The 
Global Burden of Disease 2016 study reported that 144,000 deaths globally in 2016 
were caused by drug use disorders; a rise of 15% when compared to figures in 2006 
(Naghavi et al., 2017). Scotland is in the midst of a drug related deaths crisis, and has 
observed a two fold increase in drug related deaths between 2008 (n= 574) and 2018 
(n= 1187), with Tayside experiencing the highest number of drug related deaths ever 
recorded in the region in 2018 (National Records of Scotland, 2019). Scotland has the 
highest number of drug related deaths per capita out of any EU country, and the rate is 
approximately three times higher than the rate of England and Wales (National 
Records of Scotland, 2019; Office for National Statistics, 2019). Males account for the 
majority of drug related deaths, with 72% of casualties in Scotland in 2018 being male 
(National Records of Scotland, 2019). However, Scotland has experienced a 289% 
increase in drug related deaths in women between 2008 (n= 113) and 2018 (n= 327). 
Blood borne viruses are associated with higher risk of drug related death, with HCV 
diagnosis marking PWID with double the risk of mortality (Merrall, Bird, & Hutchinson, 
2012).  
 
          The Scottish Government is committed to addressing this worrying public health 
concern, launching its new national drug and alcohol strategy in November 2018 to 
support evidence based approaches to reduce harms associated with problem drug  
use, with a particular focus on drug related deaths (Population Health Directorate, 
Scottish Government, 2018). As part of this strategy, in July 2019, the Drug Deaths 
Taskforce was convened to coordinate and prompt action to improve the health and 
wellbeing of people who use drugs, for example, by examining the evidence around 
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drug deaths prevention, publishing good practice guidelines to reduce drug use related 
harms, and identifying barriers in the delivery of addiction services. The strategy’s key 
elements focus on: treating people and their complex needs; reducing stigma and 
discrimination towards people who use drugs; tackling inequalities; providing rapid 
access to opioid substitution therapy and increasing retention rates; focusing upon 
early prevention including combating early childhood trauma that can increase future 
risk of using drugs and associated harms; and utilising a public health approach to 
reduce the number of vulnerable persons in the justice system. It is hoped that 
together, these strategic actions will curb the trend in drug related harms, and support 
individuals and their families on their road to recovery.   
           
          Opioid Substitution Therapy (OST) is considered a protective factor against both 
natural and overdose related deaths, and low threshold prescribing services are 
strongly related to lower risk of death and increased retention rates (Degenhardt et al., 
2011). PWID who are not  engaged with treatment services are considered to have a 
higher mortality risk than those in treatment, and retention in treatment is also 
considered protective against all-cause mortality and drug related death (Sordo et al., 
2017).  
 
Justification for study  
 
          The development of multidisciplinary managed care networks (MCN) in HCV care 
has transformed HCV testing and treatment services, transitioning from standard 
secondary care outpatient treatment services, to the introduction of numerous 
specialised nurse led outreach care pathways. A cohort study was conducted to 
investigate the effectiveness of these specialised HCV care pathways in Tayside, 
Scotland by evaluating clinical outcomes of HCV antibody positive individuals who 
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belonged to four subgroups based upon date of first antibody positive test, 
representing different pathways of care (Tait et al., 2017). The results of this study 
found that the introduction of multidisciplinary managed care networks in HCV 
treatment improved HCV testing, diagnosis, treatment, and SVR rates within the region 
by increasing access to testing and treatment services. Strikingly, the study found that 
the improvement in access into care for patients led to a significant reduction in risk of 
death. Individuals in the final subgroup, representing care pathways with increased 
outreach clinics and DAA treatment regimens, had a 40% reduction in risk of all-cause 
mortality, in comparison to individuals in the first subgroup, representing early care 
pathways with limited access to treatment, no specialist nurse input, and interferon 
based treatment regimens. Crucially, multivariate analysis showed that this increased 
odds of survival was sustained after SVR, HIV status and age were controlled for. The 
authors of the study posited that the associated improvement in access into care and 
HCV treatment may have led to a greater degree of engagement with health services 
and may have had a stabilizing effect on drug use behaviour.  
 
          However, this study was an observational cohort study, with limitations in power 
to infer associations between interventions and outcomes. Therefore, based on the 
current limited literature, and the scarcity of strong evidence around the impact of HCV 
diagnosis and treatment on injecting risk behaviours amongst PWID, there is clearly a 
place for a review of all the available evidence directly investigating the impact of HCV 
treatment on injecting drug use behaviour in PWID. This investigation will take the 
form of a systematic review in Chapter 2.  
 
              Additionally, at a time when Scotland, and particularly Tayside, is in the midst 
of a drug related deaths crisis, investigating the impact of HCV diagnosis and treatment 
on mortality outcomes of PWID is of great significance and has meaningful implications 
for the development of specialised HCV treatment pathways. Moreover, there is 
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concern around the potential impact of reduction in intensity of staff contact when 
transitioning from the interferon era to the DAA era of treatment.  Interferon based 
treatment required a greater intensity of staff to patient engagement due to adverse 
side effects and long treatment duration. Contrastingly, DAA based treatment has 
minimal side effects and higher cure rates (in excess of 95%) (Falade- Nwulia et al., 
2017). Thus, treatment pathways are streamlined and arguably provide less 
opportunity for patients to develop a therapeutic relationship with healthcare 
professionals involved in their care, and therefore reduced opportunities to facilitate 
change in people’s drug use behaviour, and lower risk of mortality. Therefore, the 
current project aims to investigate the impact of HCV diagnosis and treatment on 
mortality outcomes of PWID through a series of case control studies, presented in 
Chapter 3.  
 
Research questions and hypotheses 
         
          The current project aims to answer, through a series of case control studies, 
three research questions: 
 
• Does HCV diagnosis reduce a) all-cause mortality, b) drug related death among 
PWID? 
• Does engagement in HCV treatment services reduce a) all-cause mortality, b) 
drug related death among PWID? 
• Does any change observed in risk of a) all-cause mortality, b) drug related death 
depend on if the treatment is interferon based or DAA based, and intensity of 




The following hypotheses are proposed: 
 
• HCV diagnosis will reduce risk of all-cause mortality and drug related death 
among PWID. 
 
• Engagement in HCV treatment services will reduce risk of all-cause mortality 
and drug related death among PWID. 
 
• Engagement with interferon based treatment regimens will result in a greater 
reduction in risk of all-cause mortality and drug related death than engagement 















2. Impact of Hepatitis C treatment on behavioural change in relation to drug use 
in people who inject drugs: a systematic review 
 
This systematic review has been published in the International Journal of Drug Policy in 
October 2019. A copy of the publication can be found in Appendix A. 
 
Reference: Caven, M., Malaguti, A., Robinson, E., Fletcher, E., & Dillon, J. 
F. (2019). Impact of Hepatitis C treatment on behavioural change in relation to drug 
use in people who inject drugs: A systematic review. International Journal of Drug 




          Background: A systematic review was conducted to determine the impact of HCV 
treatment on injecting drug use behaviour in people who inject drugs (PWID).  
 
          Methods: A search for peer reviewed journal articles from 1991 to present day 
was conducted using the following databases: PubMed, EMBASE, CINAHL and 
PsycINFO. Studies were appraised against the following inclusion criteria: recruitment 
of PWID for HCV treatment (either interferon alpha or direct acting antivirals based); 
measurement of behavioural change in relation to drug use; studies published in 
English.  
 
           Results: Five studies investigating the impact of HCV treatment on behavioural 
change in relation to drug use amongst PWID were identified. Studies investigated the 
impact of HCV treatment on past month injecting drug use (four studies), injecting 
frequency (two studies), needle and syringe borrowing (two studies) and injecting 
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equipment sharing (three studies). Three of the four studies assessing impact of 
treatment on past month injecting frequency found treatment significantly reduced 
the odds of participants reporting past month injecting at follow up. One study found 
that there was significant reduction in weekly injecting frequency between enrolment, 
treatment and follow up. No association was found between treatment engagement 
and needle and syringe borrowing. Two out of three studies reported a significant 
decrease in injecting equipment sharing between enrolment, treatment and follow up.  
 
          Conclusions: Comparison and synthesis of results was challenging due to 
heterogeneity between studies. Moreover, four out of the five selected studies were 
conducted during the interferon era of treatment, possibly limiting the generalisability 
of the current review’s results to the new DAA treatment era. However, it is likely that 
engaging in treatment has a positive impact upon clients’ injecting drug use and 
injection equipment sharing behaviour. This raises the possibility that this may be an 




          To examine the literature investigating how, if at all, the behaviour of PWID 
changes in relation to injecting drug use when undergoing HCV treatment and during 
follow up, including changes in injecting behaviour, injecting frequency, needle and/or 








         This systematic review was conducted and reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement (Moher, Liberati, Tetzlaff, & Altman, 2009). The study was registered in 
PROSPERO (CRD42018116625). 
 
          In response to the stated objectives, a detailed research question was framed 
following the PICOS (population, intervention, comparison, outcome, study design) 
approach (Higgins & Green, 2011). The PICOS criteria were also combined with 
additional exclusion criteria. Inclusion and exclusion criteria can be found in Tables 1 




         The study population of interest was PWID of any gender and age. Studies 
focusing on non- injecting patients were excluded as we were specifically interested in 
impact of HCV treatment on behaviour change in relation to injecting drug use. PWID 
who were treated for other blood borne viruses were also excluded. Studies 
investigating impact of HCV treatment in prison populations were excluded as 
measuring behaviour change in relation to drug use in these populations is challenging. 
This is because people who are incarcerated do not have access to injecting 








          The intervention of interest is Hepatitis C treatment. Treatment can either be 
interferon alpha or directing acting antivirals based. Studies only focusing on HCV 




           Comparison groups included PWID who did not receive treatment; or PWID who 
chose to not engage in treatment post HCV diagnosis. Studies which did not utilise 
comparison groups, but compared participants’ behaviour before and after treatment, 






          The primary outcome of interest was behavioural change in relation to drug use 
e.g. injecting behaviour, needle and syringe borrowing, sharing of ancillary equipment. 










Table 1. Inclusion Criteria 
Inclusion Criteria 
• Population: people who inject drugs (PWID). 
• Intervention: Hepatitis C treatment (either interferon alpha or direct acting 
antivirals based). 
• Comparison: participants themselves i.e. behaviour measured before and after 
treatment; or PWID who did not receive treatment; or PWID who chose to not 
engage in treatment post HCV diagnosis. 
• Primary outcome: behavioural change in relation to drug use e.g. injecting 
behaviour, needle and syringe borrowing, sharing of ancillary equipment.  
• Studies published in English, utilising a quantitative or mixed- methods study 
design. 
• Studies conducted between 1991 and 2018. 
 
 
Table 2. Exclusion Criteria 
Exclusion Criteria 
• Studies utilising a purely qualitative study design; individual case studies. 
• Studies that are entirely theoretical. 
• Participants who are non- injecting patients, or PWID who were treated for other 
blood borne viruses. 
• Studies investigating the impact of Hepatitis C treatment in prison populations. 
• Studies focusing on the impact of knowledge of HCV status, and not HCV 
treatment, on behavioural change in relation to drug use. 
• Studies focusing on reinfection rates after treatment. 
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Study Designs  
 
 
          Studies utilising quantitative or mixed methods study designs such as randomised 
control studies (RCTs), non-randomised controlled clinical trials (CCTs), and prospective 
and retrospective cohort studies were included. Studies utilising a purely qualitative 





          The International Prospective Register of Systematic Reviews (PROSPERO) was 
searched to confirm no similar review had already been conducted. A search for peer 
reviewed journal articles was conducted using PubMed, EMBASE, CINAHL and 
PsycINFO, on 9th November 2018. A grey literature search of the International Network 
on Hepatitis in Substance Users (INHSU) conference abstracts was also conducted. This 
symposium was specifically targeted as it is dedicated to research focusing on Hepatitis 
C in the cohort of interest, namely PWID. A time parameter was implemented for 
studies conducted from 1991 to 2018, as 1991 was the year interferon became 
commercially available for treatment of Hepatitis C. An inclusive list of search terms in 
line with each search topic was generated to develop an effective search strategy.  
Both keywords and indexed subject headings (MeSH and EMTREE terms) were included 
in the formulation of search strings for each database search. Search topics included 
“Hepatitis C treatment”, “behaviour change” and “drug use”. Table 3 includes a full list 
of search terms utilised in the search strategy, grouped by search topic. Manual 
searches of reference lists of selected studies were also conducted. Searches were 

















          Fig. 1 shows a PRISMA flowchart of the selection process. Screening of the search 
strategy results was conducted by two reviewers. The first phase involved importing all 
citations into EndNote X8 and removing duplicate records. Titles were screened, and 
irrelevant records removed. Abstracts were then assessed using the inclusion and 
exclusion criteria. All remaining records were then subjected to a full text evaluation 
for eligibility. Discrepancies in judgements were resolved by discussion within the 
whole research team until consensus was met.  
Hepatitis C treatment Behaviour change Drug use 
Hepatitis C 
treatment/therapy^ 




Behavi* benefit Drug misuse 
 Drug use change* Drug use 
 Inject behavi* Drug disorder 
 Risk behavi* Drug addict* 
 Inject* frequency Drug dependen* 









































































Data extraction and synthesis  
 
          Data from selected studies was extracted using a piloted data extraction form by 
one reviewer (MC). The following variables were collected: first author, title, 
publication year, full paper or abstract, primary aim, study design, location, setting, 
total study duration, follow up period, sample characteristics, sample size, 
intervention, outcome/ measure of behaviour change, main results, conclusions. The 
authors of Malaguti et al. (2019) were contacted for clarification regarding follow up 
period in their study. The authors of Artenie et al. (2019) were contacted to obtain 
updated data, and they kindly provided an unpublished manuscript relating to their 
INHSU conference abstract. The data synthesis used an Economic and Social Research 
Council (ESRC) style quantitative narrative synthesis (Popay et al., 2006). Heterogeneity 
between studies was manually assessed by reviewers. This was used as there was too 




         Risk of bias in individual studies was assessed using the Quality Appraisal Checklist 
for quantitative intervention studies by NICE public health guidance (National Institute 
for Health and Care Excellence, 2012). The checklist enables both the evaluation of the 
study’s internal and external validity, addressing aspects of study design such as 
participant characteristics, definition of and allocation to intervention/control 
conditions, and methods of analyses. Each study was awarded separate overall quality 
ratings for internal and external validity, with ratings ranging from 1 to 3. Quality 
appraisal for four studies was independently conducted by two reviewers (MC and 
AM), with discrepancies in ratings resolved by discussion until consensus was met. A 
Cohen’s kappa coefficient (κ) was calculated to assess inter-rater agreement, κ = .61, p 
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< .001. This kappa (κ) value represents a substantial agreement (Landis & Koch, 1977). 
A third reviewer (ER), along with the first reviewer (MC), conducted a quality appraisal 
for the fifth study. This was necessary to reduce bias as the second reviewer (AM) was 
an author of the study. A Cohen’s kappa coefficient (κ) was calculated to assess inter-
rater agreement, κ = .68, p < .001, representing a substantial agreement (Landis & 






          Overall, 864 records were identified through database and conference abstract 
searching, 723 of which remained after duplicates were removed. After assessment of 
titles and abstracts, 21 records remained. Sixteen records were removed based on full-
text assessment, with the most common reasons being that studies focused on impact 
of HCV knowledge on injecting behaviour (n= 6) or studies focused on reinfection after 
treatment (n= 7). Five studies were included in the final narrative synthesis (see Fig. 1).  
 
Characteristics of selected studies 
 
         Characteristics and findings of selected studies are summarised in Table 4. Studies 
evaluated impact of treatment on injecting drug use by recruiting participants from a 
number of settings including tertiary hospitals; GP and primary care clinics; community 
clinics; drug and alcohol treatment clinics; private medical practices; and injecting 
equipment provision services. There were four prospective cohort studies and one 
retrospective cohort study. Two studies included comparison groups in their study 
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design. Alavi et al. (2015) utilised PWID that did not receive treatment as their 
comparison group. Artenie et al. (2017) utilised three comparisons groups, namely 
PWID who did not engage in treatment post- diagnosis; PWID who did not engage in 
treatment due to spontaneous clearance of the virus; and HCV positive PWID who 
were not eligible for treatment due to contra-indications.  
 
          Four studies investigated past month injecting drug use; two studies investigated 
injecting frequency; two studies investigated needle and syringe borrowing; and three 
studies investigated ancillary injecting equipment sharing. Of the five studies selected, 
four studies involved treatment with pegylated interferon alpha and/or ribavirin, with 
only one study involving treatment with direct acting antivirals (DAAs). Follow up 
periods ranged from 24 weeks to 2 years. In the sampled studies, the majority of 
participants were Caucasian males, with a mean age ranging from 32- 47 years old, 
who had injected drugs in the last 6 months prior to study enrolment. Two of the five 
selected studies solely recruited participants with acute HCV infection (Alavi et al., 
2015; Artenie et al., 2017). Recruiting patients for treatment with acute HCV infection 
is not reflective of standard clinical practice, as these patients have a 20-30% of 
spontaneous clearance during the acute phase of the infection, making treatment 
uneconomical at this stage (Aisyah, Shallcross, Hully, O’Brien & Hayward, 2018). 
However, effect on injecting behaviour may still be relevant.
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Follow up period  
Setting Participant 
characteristics- 
age, gender, past 
month injecting 
drug use, on OST,  
HCV status 
Treatment Main Findings 
Alavi et al. (2015) 
 
Australia 
Past month  
Injecting drug use, 









study (PWID that 
did not receive 
treatment)  
 





Mean age= 32 
years (25- 39 
years), 69% male, 
past month 
injecting drug use= 
45%, on OST= 





treatment (up to 
24 weeks) 
 
Injecting drug use 
during follow up 




during follow up 
was not associated 
with treatment. 
Treatment 




during follow up. 












study (PWID who 
did not engage in 
treatment post-
diagnosis; did not 






Mean age= 35.6 
years, 78% male, 
past month 
injecting drug use= 
87.4%, on OST= 











likely to report 




 clearance; not 
eligible for 















France, UK and 
USA 
Past month 
injection drug use, 
needle/ syringe 
sharing, hazardous 














Mean age= 47 
years, 74% male, 
past month 
injecting drug use= 
62%, on OST= 














Decrease in needle 
and syringe 
sharing during and 
following 
treatment. 



















84 participants (18 
to 70 years), 69% 
male, past month 
injecting drug use= 
100%, on OST= 














future time points. 
Largest reduction 












and the UK 
Past month  
injection 























Median age= 41 
years (35- 50 
years), 83% male, 
past month 
injecting drug use= 
59%, on OST= 





treatment (up to 
24 weeks) 
 





were found in 
>daily injecting, 
use of non-sterile 








Risk of bias in individual studies 
 
          Table 5 provides detailed quality appraisal scores for each included study. The 
results of the scoring process suggests that Artenie et al. (2017) was the 
methodologically most robust study. Overall, the selected studies scored very highly on 
external validity. However, several issues of internal validity can be discussed. For 
instance, the occurrence of losses to follow up may have caused selection bias in 
several studies, with sizeable differences in socio-demographic characteristics between 
participants who remained, versus lost to follow up. For example, Midgard et al. (2017) 
found that participants who remained in 12 weeks follow up were more likely to be 
employed, have higher education levels, had less history of incarceration, and had 
injected more often in the last month, in comparison to those lost to follow up. 
Therefore, it is possible that those remaining in follow up were more likely, for 
instance, to have greater access to social support, impacting on their ability to engage 
in treatment and facilitate behavioural changes in relation to their drug use. Another 
issue of internal validity is the lack of comparison groups in some studies, e.g. Artenie 
et al. (2019) and Midgard et al. (2017), making it challenging to attribute behavioural 
changes to the intervention, i.e. HCV treatment. A final point to note is the quality 
assessment tool’s appraisal of the outcome variable’s reliability. According to the 
Quality Appraisal Checklist’s guidelines, outcome variables that are measured 
subjectively, e.g. self-report, are to be scored poorly and could introduce information 
bias (National Institute for Health and Care Excellence, 2012). As all selected studies 
utilised a self-reported measure of injecting risk behaviours, they were all poorly 
scored for this part of the appraisal process. However, research has demonstrated that 
self-reported drug use among PWID is reliable and valid (Darke, 1998). Therefore, it is 





Table 5. Quality appraisal ratings for each included study 
 Alavi et al. 
(2015) 
Artenie et al. 
(2017) 
Malaguti et al. 
(2019) 
Midgard et al. 
(2017) 
Artenie et al. 
(2019) 
1.1 Description of source population 3 3 3 3 1 
1.2 Representativeness of eligible population 3 3 3 3 2 
1.3 Representativeness of selected participants 2 3 2 2 2 
2.1 Allocation to intervention or comparison NA NA NA NA NA 
2.2 Description of intervention and comparison 3 3 2 3 2 
2.3 Concealment of allocation NA NA NA NA NA 
2.4 Blinding to exposure/comparison NA NA NA NA NA 
2.5 Adequacy of exposure to intervention/comparison NA NA NA NA NA 
2.6 Contamination NA NA NA NA NA 
2.7 Similarity of other interventions to groups 3 3 NA NA NA 
2.8 Lost to follow up  1 2 2 2 1 
2.9 Setting reflects usual UK practice 2 2 3 3 2 
2.10 Intervention reflects usual UK practice 2 2 3 3 2 
3.1 Reliability of outcome measures 1  1 1 1 1 




3.3 Assessment of important outcomes NA NA NA NA NA 
3.4 Relevance of outcomes 3 3 3 3 3 
3.5 Similarity of follow up times across groups NA NA NA NA NA 
3.6 Meaningfulness of follow up times 3 3 3 3 3 
4.1 Similarity of groups at baseline 3 3 NA NA NA 
4.2 Intention to treat (ITT) analysis NA NA NA NA NA 
4.3 Study’s power to detect an intervention effect 2 2 2 2 2 
4.4 Estimates of effect size 3 3 3 3 3 
4.5 Appropriateness of analytical methods  3 3 3 3 2 
4.6 Precision of intervention effects 3 3 3 3 3 
5.1 Internal validity  2 3 2 2 2 








Results of individual studies 
 
Impact of treatment on past month injecting drug use 
 
          Four studies investigated the impact of treatment on past month injecting drug 
use at various time points during treatment and follow up, assessed dichotomously 
(Alavi et al., 2015; Artenie et al., 2017; Artenie et al., 2019; Midgard et al., 2017). Alavi 
et al. (2015) reported no association between HCV treatment and past month injecting 
drug use during 24 weeks follow up, when comparing PWID who did and did not 
receive treatment (aOR 1.06, 95% CI 0.93- 1.21, n= 124). However, this study did not 
differentiate between participants based on their reasons for not engaging in 
treatment after study enrolment, possibly explaining the non-significant results of the 
study as untreated participants are arguably a more heterogeneous cohort. A second 
study by Artenie et al. (2017) did make this distinction, evaluating the impact of 
treatment on injecting drug use at one year follow up when comparing people who 
received treatment, and three comparison groups: people who spontaneously cleared 
the virus and did not require treatment; people who were not eligible for treatment 
due to contra-indications to therapy; and people who voluntarily chose not to engage 
in HCV care. Results showed that the received treatment group were less likely to 
report injecting drug use at follow up in comparison to the voluntary non- engagement 
group (aOR 0.18, 95% CI 0.04- 0.76, n=87). The odds of reporting injecting drug use at 
follow up amongst the spontaneous clearance (aOR 0.34, 95% CI 0.08–1.40, n=87) and 
contra- indications to therapy groups (aOR 0.24, 95% CI 0.05– 1.22, n= 87), were not 
significantly lower in comparison to the voluntary non- engagement group. This finding 
is supported by Midgard et al. (2017) who found that there was a significant reduction 
in any past month injecting drug use during treatment and 12 week follow up (OR 0.89, 
95% CI 0.83– 0.95, n= 93), with the likelihood of injecting halved at treatment 




based treatment on past month injecting drug use and found that there was an overall 
significant reduction in opioid injecting (OR: 0.95, 95% CI 0.92- 0.99, n= 190) between 
treatment initiation and 2 year follow up (Artenie et al., 2019). However, no reduction 
in stimulant (cocaine and amphetamine) injecting was reported (OR 0.98, 95% CI 0.94-
1.02, n=190). 
 
Impact of treatment on injecting frequency 
 
          Two studies investigated the impact of treatment on injecting frequency. 
Midgard et al. (2017) measured ≥ daily injecting as a proxy for past month injecting 
frequency, and found that the proportion of participants who reported ≥ daily injecting 
did not significantly change during treatment and follow up (OR 0.98, 95% Cl 0.89- 
1.07, n= 93). It is notable that injection risk behaviours amongst participants in this 
study were low at baseline, with only 28% of participants who achieved 12 weeks 
follow up reporting ≥ daily injecting at enrolment. Moreover, the authors mention a 
lack of statistical power due to the relatively small sample size, providing a second 
explanation of lack of significant findings. A second study by Malaguti et al. (2019) 
investigated changes in weekly injecting frequency between enrolment, during 
treatment and at 6 months follow up. Results showed a significant decrease in injecting 
frequency between enrolment and future time points (χ2 (7) = 36.44, p< .001, n= 32), 
with the largest reduction in injecting reported between enrolment and week 8 of 
treatment, maintained through to 6 months follow up. A criticism of this study may be 
the high degree of incomplete data, with only 38% of participants providing data for all 







Impact of treatment on needle and syringe borrowing 
 
          The impact of treatment on needle and syringe borrowing was investigated by 
two studies. One such study by Alavi et al. (2015) found that treatment was not 
associated with a reduction in needle and syringe borrowing during follow up, when 
comparing PWID who did and did not receive treatment (aOR 0.99, 95% CI 0.89, 1.07, 
n= 124). A second study found that treatment receipt did not significantly facilitate a 
reduction in use of non-sterile needles (OR 0.94; 95% CI 0.79–1.12, n= 93) (Midgard et 
al., 2017). 
 
Impact of treatment on injecting equipment sharing 
 
          Facilitation of a reduction in injecting equipment sharing by treatment was 
explored in three studies. One study reported a significant decrease in injecting 
equipment sharing, including mixing container, filter and water, during treatment and 
24 weeks follow up (aOR 0.85, 95% CI 0.74- 0.99, n=124), with a reduction in the 
number of participants reporting sharing from 54% at baseline to 17% at follow up 
(Alavi et al., 2015). In contrast Midgard et al. (2017) reported no association between 
treatment and injecting equipment sharing, including spoons, mixing containers, drug 
solution, water and filter, during treatment and 12 week follow up (OR 0.87, 95% CI 
0.70–1.07, n= 93). One study investigating the impact of DAA based treatment on 
behavioural outcomes reported a significant reduction in the number of participants 
reporting needle and syringe sharing during treatment and 2 year follow up (OR 0.87, 
95% CI 0.80- 0.94, n= 190) (Artenie et al., 2019). However, it must be noted that 
although a reduction in needle and syringe sharing during and after treatment was 
noted, the baseline prevalence of this risk behaviour was low at only 16% of the 62% of 






Summary of evidence 
 
          In spite of the concerns around diagnosing and treating PWID for Hepatitis C, 
there is a dearth of research on the impact of engaging in treatment on behavioural 
change in relation to drug use in this population. The current review only identified five 
studies which directly measured behavioural change outcomes in PWID engaged in 
treatment. As a consequence of the limited number of studies identified, and 
variations in follow up times, behavioural outcomes, and treatment interventions, 
drawing conclusions around whether treatment engagement is effective in reducing 
injecting drug use and injecting risk behaviours is problematic.  
 
          The most common outcome measure of behaviour change in relation to drug use 
in the selected studies was past month injecting drug use. Three of the four studies 
assessing this outcome found treatment significantly reduced the odds of participants 
reporting past month injecting at follow up (Artenie et al., 2017; Artenie et al., 2019; 
Midgard et al., 2017). However, due to variations in study design, comparing the 
findings of these separate studies is challenging. Accordingly, combining the data on 
these results to conduct a meta- analysis was deemed inappropriate. Additionally, it 
can be argued that dichotomously measuring past month injecting drug use is limiting 
in regards to providing insight into the impact of treatment on injecting behaviours. 
Combined with infrequent measurements of injecting drug use, it could be suggested 
that the results of these studies simply reflect natural fluctuations in injecting 
frequency among PWID, and do not accurately reflect a reduction in injecting drug use. 
However, taken together, these findings suggest that engaging in treatment may result 




PWID for Hepatitis C is not feasible due to concerns around treatment causing an 
increase in injecting risk behaviours (Schaefer, Sarker, & Diez- Quevedo, 2013). 
Moreover, these findings support the notion that treatment engagement may lower 
the risk of HCV transmission within the PWID population, providing support for 
accessibility to treatment. 
 
          In regards to impact of treatment on other behavioural changes related to drug 
use, findings are more inconsistent. For instance, of the two studies which investigated 
the impact of treatment on injecting frequency, only one study observed a significant 
decline in injecting frequency between enrolment, treatment, and follow up (Malaguti 
et al., 2019). Nonetheless, comparing the findings of these studies is not suitable due 
to the contrasting measurements of injecting frequency; namely weekly injecting, 
measured as a continuous variable (Malaguti et al., 2019), and ≥ daily injecting, 
measured as a binary variable (Midgard et al., 2017).  
 
          Both studies investigating change in needle and syringe borrowing found no 
association between treatment engagement and reduction in these risk behaviours 
(Alavi et al., 2015; Midgard et al., 2017). Although no significant decline was observed 
in either study, the fact that such risk behaviours remain stable throughout treatment 
and follow up has meaningful implications for risk of reinfection and onward 
transmission. It should also be considered that the availability of other services, for 
example, needle syringe programs and opioid substitution therapy, across countries 
where the studies were conducted may impact drug use behaviour. For instance, in 
countries where injecting equipment provision is low, patients may have less 
opportunity to change their injecting risk behaviours due to lack of availability of sterile 
equipment. Additionally, self-stigma may impact patients’ willingness to report sharing 
behaviour, especially in the context of settings where self-reporting of ongoing risk 




behaviours after treatment is critical to optimise patients’ chances of achieving 
sustained viral responses and to reduce HCV prevalence at a population level 
(Hickman, De Angelis, Vickerman, Hutchinson, & Martin, 2015). Of the three studies 
investigating the impact of treatment on injecting equipment sharing, two studies 
reported significant decreases in such behaviour between enrolment, treatment and 
follow up. However, of these two studies, one study by Artenie et al. (2019) was 
conducted during the DAA era of treatment, making the findings of this study 
incomparable to the other studies investigating this behaviour change.  
 
Limitations of review 
 
          The predominant limitation of the current review was the number of studies that 
met the inclusion criteria and the lack of comparability between studies. As a 
consequence, a meta- analysis of findings was not possible. Therefore, future reviews 
may seek to employ a more broadly inclusive eligibility criterion, including, for 
example, the inclusion of purely qualitative studies. Including studies of this design may 
provide a more nuanced and informed insight into patients’ treatment experiences and 
impact on their drug use behaviour. However, disadvantages of qualitative research 
include clients’ reporting biases due to researcher presence, and issues of anonymity 
and confidentiality. Secondly, inclusion of bio-behavioural observational studies, such 
as the Needle Exchange Surveillance Initiative (NESI), may be advantageous in order to 
measure and monitor patients’ injecting risk behaviours over time. Therefore, it could 
be argued that the strict search strategy was a limitation of the review. However, the 
inclusion of grey literature, such as conference abstracts, is a strength.  
 
          It is clear that future research should focus on the reasons why engaging in 




limitation of the review was that four of the five selected studies were conducted 
during the interferon era of treatment. In particular, the characteristics of people 
undergoing interferon treatment may potentially be different to those undergoing DAA 
treatment. For example, those treated using interferon based therapy may have 
experienced more adverse treatment consequences, such as associated psychiatric 
conditions, in comparison to those treated using the DAA based therapy.  
 
         Moreover, the reasons why engaging in treatment facilitates a positive behaviour 
change in relation to injecting drug use may be disparate between the aforementioned 
treatment groups. Consequently, the results of the current review may not give insight 
into the impact of treatment on injecting risk behaviours in the new DAA based 
treatment era, with future research clearly needed to clarify this issue. Also, the review 
was hindered by the inclusion of studies with selection bias of participants. All five 
studies involved clinical trial participants, who were arguably more willing to engage in 
treatment than the source PWID population. This was characterised by relatively low 
lost to follow up rates in some studies. Thus, the results of the included studies may 
not be representative of the wider population of PWID engaging in treatment. A final 
limitation of the review was that all included studies had sampling issues related to 
power, for instance as a result of small sample sizes and loss to follow up, and may 
explain lack of significant findings in some studies. Reasons for losses to follow up are 
complex, but may include, for instance, sociodemographic characteristics of study 




           Five studies investigating the impact of HCV treatment on behavioural change in 




behaviour change in relation to drug use was past month injecting drug use, with three 
out of four studies reporting treatment significantly reduced the odds of participants 
reporting past month injecting at follow up. Studies also reported significant reductions 
in injection equipment sharing between enrolment, treatment and follow up; no 
significant changes in needle and syringe borrowing; and varying results in regards to 
impact of treatment on injecting frequency. Comparison and synthesis of results was 
challenging due to heterogeneity of follow up times, treatment interventions, and 
measures of behavioural outcomes. For future research, it would be optimal for the 
research community to report injecting risk behaviour in a standardised manner to 
enable comparison and strengthen conclusions of published literature. Four out of the 
five selected studies were conducted during the interferon era of treatment, possibly 
limiting the generalisability of the current review’s results to the new DAA treatment 
era. However, results suggest the benefits of engaging in HCV care stretch beyond liver 
morbidity outcomes, with treatment positively impacting on patients’ injecting drug 
use and injection equipment sharing behaviour. These findings have relevance to the 
“treatment as prevention” model of Hepatitis C care, risk of reinfection and onward 













3. Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of 
People Who Inject Drugs, a service evaluation, the Hooked C project 
 
This study has been published in Journal of Viral Hepatitis in January 2020. A copy of 
the publication can be found in Appendix B. 
 
Reference: Caven, M., Robinson, E. M., Eriksen, A. J., Fletcher, E. H., & Dillon, J. 
F. (2020). Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour 
of People Who Inject Drugs, a service evaluation, the Hooked C project. Journal of Viral 




          Introduction: There is emerging evidence that HCV treatment engagement is 
associated with change in drug use behaviours and reduced drug related death rates 
amongst PWID. The project aims to investigate whether HCV diagnosis and treatment 
engagement reduces all-cause mortality and drug related death, and whether any 
effect is dependent on treatment regimen and intensity of engagement with staff.  
 
          Methods: Case control studies comparing: PWID with active HCV infection (PCR 
Positive) to PWID HCV infected but spontaneously resolved (PCR Negative); PCR 
Positive patients who engaged with treatment services to non-engagers; and patients 





          Results: No differences in risk of all-cause mortality or drug related death 
between PCR Negative controls and PCR Positive cases were detected. The odds of all-
cause mortality was 12.2 times higher in non-engaging persons compared to treatment 
engaging cases (aOR 12.15, 95% CI 7.03- 20.99, p < 0.001). The odds of a drug related 
death was 5.5 times higher in non-engaging persons compared to treatment engaging 
cases (aOR 5.52, 95% CI 2.67- 11.44, p < 0.001). No differences in risk of all-cause 
mortality or drug related death between interferon treated cases and DAA treated 
controls were detected.  
 
         Conclusions: HCV treatment engagement is significantly protective against all-
cause mortality and drug related death. This engagement effect is independent of 
treatment regimen, with the introduction of DAA therapies not increasing risk of drug 
related death, suggesting intensity of HCV therapy provider interaction is not an 




          The current project aims to answer, through a series of case control studies, 
three research questions: 
 
• Does HCV diagnosis reduce a) all-cause mortality, b) drug related death among 
PWID?  
• Does engagement in HCV treatment services reduce a) all-cause mortality, b) 




• Does any change observed in risk of a) all-cause mortality, b) drug related death 
depend on if the treatment is interferon based or DAA based, and intensity of 
engagement with staff? 
 
           Three case control studies will be carried out, comparing:  
 
• PWID with active HCV infection (PCR Positive) vs PWID who were HCV infected 
but cured spontaneously (PCR Negative) to elucidate whether HCV diagnosis 
impacts risk of mortality 
• PCR Positive patients who engaged vs did not engage with treatment services to 
assess if outcomes are dependent on engagement 
• Pegylated interferon alpha treated patients vs Direct acting antiviral patients to 
explore the effect of intensity of HCV therapy provider interaction on outcomes  
 
          The following hypotheses are proposed: 
 
• HCV diagnosis will reduce risk of all-cause mortality and drug related death 
among PWID. 
• Engagement in HCV treatment services will reduce risk of all-cause mortality 
and drug related death among PWID. 
• Engagement with interferon based treatment regimens will result in a greater 
reduction in risk of all-cause mortality and drug related death than engagement 










          Approval for access to relevant data from all data sources was obtained from the 
Caldicott Guardian of NHS Tayside Information Governance Team (issued November 




          We employed a retrospective case control study design, matching participants by 
age and sex.  
 
Data sources and data linkage 
 
           The main data source utilised was the Tayside Hepatitis C Clinical Database. This 
database is kept for clinical purposes to record patients tested for Hepatitis C, awaiting 
treatment, on treatment, cured and re-infected in Tayside, Scotland. Data collected 
from this database included demographic information, risk factors, laboratory tests, 
follow up and treatment outcomes. Patients identified from this database and forming 
the cohort were electronically linked with electronic medical records and the Tayside 
Drug Deaths Database, using patients’ Community Health Index (CHI) numbers (unique 
identification numbers given to every patient registered with a GP in Scotland). 
Information on patients’ mortality status was obtained via electronic medical records. 




Tayside Drug Deaths Database which records data on all drug related deaths in Tayside 
and feeds into national reporting mechanisms through NHS Information Services 
Division and also informs the work of the Tayside Drug Death Review Group.  
 
Identification of selected cohort 
 
           Inclusion and exclusion criteria are presented in Table 6. From the Tayside 
clinical database, a cohort of individuals was identified whose risk factor for HCV was 
injecting drug use. Therefore, the definition of PWID in our study is people who have 
“ever injected” drugs, with no differentiation between recent/active and former PWID. 
Although there may be variation in the cohort regarding recent/active drug use, it was 
decided that it was appropriate to include “former” PWID, i.e. those who may have 
ceased injecting, as a proportion of HCV infections are found in this group. It could be 
argued that the inclusion of former PWID in the cohort could lead to biases due to 
differences in injecting behaviours and therefore risk of mortality, when compared to 
current PWID. However, we only included individuals who were tested/treated from 
2008 onwards, which reduces the likelihood that we have included a significant 
number of former PWID. Moreover, given the relapsing nature of drug dependence, 
determining a cut off to define current/recent vs former PWID is problematic and leads 
to biases. Therefore, the definition that would least likely bias the study was chosen, by 
being inclusive.  Individuals with other risk factors, such as transfusion of blood 
products or maternal transmission were excluded as we were specifically investigating 
the impact of HCV treatment on the behaviour of PWID. Individuals with non-Tayside 
postcodes were excluded as drug related death outcomes would not be registered for 
non-Tayside individuals on the Tayside Drug Deaths Database. Individuals co-infected 
with other blood borne viruses e.g. HIV or Hepatitis B, were excluded from the selected 
cohort as these individuals would have differing mortality rates and treatment 




on treatment before January 2008 were excluded as the MCN for HCV care in Tayside 
was introduced in 2008 and this substantially changed the care pathways. Lastly, 
individuals who were tested or initiated treatment after November 2017 were 
excluded to allow for a minimum of one year of follow up.  
 
Table 6. Inclusion/Exclusion Criteria 
Inclusion Criteria 
• Risk factor for HCV: injecting drug use 
• Postcode within Tayside 
• Tested/initiated treatment between January 2008 and November 2017 
Exclusion Criteria 
• Risk factor for HCV: high prevalence country, blood products, maternal 
transmission, renal dialysis 
• Postcode out with Tayside 
• Co-infected with other blood borne viruses e.g. Hepatitis B, HIV 
• Tested/initiated treatment before January 2008 
• Tested/initiated treatment after November 2017 
 
 
          For each analysis, cases and controls were defined differently, although derived 
from the same cohort previously described. For analysis 1, all individuals who tested 
HCV antibody positive were identified. Cases were defined as PWID with active HCV 
infection (PCR Positive), and controls were defined as PWID who were HCV infected 
but cured spontaneously (PCR Negative). For analysis 2, all individuals who tested HCV 
PCR Positive were identified. Cases were defined as PCR Positive patients who engaged 
with treatment services, and controls were defined as PCR Positive patients who did 
not engage with treatment services. For analysis 3, all individuals who were PCR 
Positive and engaged with treatment were identified. Cases were defined as pegylated 
interferon alpha treated patients, and controls were defined as DAA treated patients. 




52- 67, 68- 83, 84+) and sex. Controls from the respective categories were randomly 
selected using an online random number generator.  
 
Outcome variables  
 
All-cause mortality and drug related death 
 
          The definition of a drug related death is a death where the underlying cause is: 
drug abuse or drug dependence; or drug poisoning (intentional or accidental) that 
involves any substance controlled under the Misuse of Drugs Act 1971 (National 
Records of Scotland, 2019). The National Records of Scotland uses the ICD 10 
classification system to identify cases of drug-related death once a death certificate has 




Treatment engagement  
 
          “Treatment engagement” was defined as engaging with healthcare professionals 
and commencing treatment. All patients who commenced treatment were classified as 
“treatment engagers”, irrespective of how many days/weeks of treatment they 
completed, whether they completed their entire course of treatment or not, and the 
outcome of their treatment, e.g. if a sustained viral response (SVR) was achieved. 





Opioid substitution therapy (OST) 
 
          Data was collected on individuals’ OST status around the time of testing or 
treatment. Specifically, for analysis 1 (PCR Negative vs PCR Positive) and analysis 2, 
(Treatment Engagers vs Non-Engagers), data was collected on whether individuals 
were on OST at the time of HCV RNA PCR testing, +/- 6 months. For analysis 3 
(interferon vs DAA treated patients), data was collected on whether individuals were 




          Data was collected on individuals’ cirrhosis status. Individuals were classified as 
being cirrhotic if their liver stiffness (FibroScan) score was 12.5 kPa or above, or their 




         Data was collected on individuals’ sustained virologic response (SVR) status. SVR 









Statistical analysis  
 
         All statistical analyses were performed using IBM SPSS Statistics 22. For analysis 1 
(PCR Negative vs PCR Positive) and analysis 2 (Treatment Engagers vs Non-Engagers), 
follow up began from first antibody positive test. For analysis 3 (interferon vs DAA 
treated patients), follow up began from date of treatment commencement. For all 
analyses, survival time was exactly observed or censored at the last follow up date (31st 
December 2018). Baseline characteristics were summarised using descriptive statistics. 
Inter-correlations between predictor variables were summarised using Pearson’s 
correlational analyses. Point-biserial correlations were carried out to assess the 
association between categorical and continuous variables.  
 
          Kaplan Meier survival analysis was performed to investigate differences in the 
rates of all-cause mortality and drug related deaths between cases and controls. 
Comparison of survival curves was performed using log rank tests. Binary logistic 
regressions were used to compare the odds of all-cause mortality and dying of a drug 
related death among cases with those among controls. We estimated odds ratios (ORs) 
and 95% confidence intervals for all comparisons and adjusted all models for the 
matching variables; age and sex. A number of other covariates were also included in 
certain models; SVR, OST, and cirrhosis.  
 
Assumptions for binary logistic regressions 
 
          Prior to running the binary logistic regressions, the assumptions underlying this 





           Firstly, binary logistic regression requires the dependent variable to be 
categorical, and both dependent variables (all-cause mortality and drug related death) 
met this assumption.  
 
           Secondly, for all analyses, the assumption of multicollinearity was met after 
inspection of the correlation matrices revealed no evidence of strong correlations 
between predictor variables. 
 
           Thirdly, for all analyses, the assumption of independence of errors was met after 
it was determined that the error terms were independent. 
 
           Lastly, the assumption of linearity was met, with non-significant Hosmer and 
Lemenshow tests for all analyses (p = 0.10- 0.71). 
 
Coding of categorical predictors 
 
          Dummy variables were calculated for all categorical predictors: sex, SVR, OST, 
cirrhosis, PCR status, Treatment Engagement, and Treatment Regimen. For sex, males 
were used as a baseline, with which females were compared (Male vs Female). For 
SVR, not achieving SVR was used as a baseline, with which achieving SVR was 
compared (No vs Yes). For OST, not on OST was used as a baseline, with which on OST 
was compared (No vs Yes). For cirrhosis, non-cirrhotic patients were used as a baseline, 
with which cirrhotic patients were compared (No vs Yes). For PCR status, PCR Negative 
controls were used as a baseline, with which PCR Positive cases were compared 
(Negative vs Positive). For Treatment Engagement, Treatment Engaging cases were 




(Engagers vs Non-Engagers). Lastly, for Treatment Regimen, DAA treated controls were 


























Analysis 1- PCR Positive vs Negative  
 
          A total of 3431 individuals who tested HCV antibody positive were identified. Of 
these, 386 PCR Negative controls and 918 PCR Positive cases met the inclusion criteria 
(see Figure 2), and were randomly matched by age group and sex, leading to 386 PCR 
Negative controls and 386 PCR Positive cases included in the study. 
 
          Baseline characteristics of cases and controls are presented in Table 7. The 
majority of cases (96.4%) and controls (96.1%) were under the age of 65 years, and 
male (57.0%).  
 
          During the study’s follow up period, there were 135 deaths out of 722 individuals 
who were antibody positive; 72 (53.3%) deaths were in PCR Positive cases, and 63 
(46.7%) were in PCR Negative controls. Of 135 deaths, 63 were classified as drug 
related deaths; 34 (54.0%) were in cases, and 29 (46.0%) were in controls.  
 
          For all-cause mortality, the survival distributions for the two groups were not 
significantly different, χ2(2) = .425, p =.515 (see Figure 3). No difference in risk of all-
cause mortality between PCR Negative controls and PCR Positive cases was detected 
(aOR 1.18, 95% CI 0.80- 1.73, p = .40), after adjustment for age and sex (see Table 8).  
 
          For drug related deaths, the survival distributions for the two groups were not 




related death between PCR Negative controls and PCR Positive cases was detected 















































Figure 2. Selection of PCR Positive cases and PCR Negative controls based on 
inclusion/ exclusion criteria.  
3431  
Individuals testing HCV antibody 
positive   
 Potential Controls= PCR Negative: 
859 
Following exclusion of individuals with 
unknown PCR results (N= 11) 
 Potential Cases= PCR Positive: 2499 
Following exclusion of individuals with 
unknown PCR results (N= 62) 
 
800 
Following exclusion of individuals with 
other risk factors e.g. blood products, 




Following exclusion of individuals with 
other risk factors e.g. blood products, 
high prevalence country (N=211) 
 
 640  
Following exclusion of individuals with 
postcodes out with Tayside (N= 160) 
 
 2247 
Following exclusion of individuals co- 
infected with other BBVs (N=41) 
 
 386 PCR Negative controls  
Following exclusion of individuals 
tested before 2008/tested after 
November 2017 (N= 254) 
 
1999 
Following exclusion of individuals with 
postcodes out with Tayside (N= 248) 
 
918 PCR Positive cases 
Following exclusion of individuals 
tested before 2008/tested after 
November 2017 (N= 1081) 
 
Potential Controls= PCR Negative: 
870 





Figure 3. Kaplan Meier survival curve for time from first antibody positive test to all-











Figure 4. Kaplan Meier survival curve for time from first antibody positive test to drug 










 Table 7. Baseline characteristics of PCR Positive cases and PCR Negative controls (Analysis 1); Treatment Engaging cases and 









 Analysis 1 Analysis 2 Analysis 3 
 Cases (N = 386) Controls (N = 386)  Cases (N = 263) Controls (N = 263) Cases (N = 266) Controls (N = 266) 
Age, years (mean ± SD) 
 
41.77 ± 10.9 41.56 ± 10.92 42.86 ± 10.64 42.98 ± 11.17 43.20 ± 9.20 43.80 ± 9.09 
Age ≥ 65 years  
 
14 (3.6%) 15 (3.9%) 9 (3.4%) 7 (2.7%) 3 (1.1%) 6 (2.3%) 
Male  
 




















Table 8. Summary of logistic regression analyses for control variables (age, sex, SVR, OST, and cirrhosis), PCR status (Analysis 1), 
Treatment Engagement (Analysis 2), and Treatment Regimen (Analysis 3) predicting all-cause mortality 




  95% CI for Odds Ratio 
 B (SE) Lower Odds Ratio Upper 
Analysis 1     
           Constant -3.82 (0.42)    
           Age  0.05* (0.01) 1.04 1.05 1.07 
           Sex (Male vs Female) -.23 (0.20) 0.53 0.79 1.18 
           PCR status (Negative vs Positive) 0.16 (0.20) 0.80 1.18 1.73 
           R2 (Cox & Snell)= .06     
Analysis 2      
           Constant -6.12* (0.71)    
           Age  0.08* (0.01) 1.05 1.08 1.11 
           Sex (Male vs Female) -0.40 (0.27) 0.40 0.67 1.13 
           OST (No vs Yes) 0.54* (0.25) 1.05 1.71 2.80 
           Treatment Engagement (Engagers vs Non Engagers) -2.50* (0.28) 7.03 12.15 20.99 
           R2 (Cox & Snell)= .25     
Analysis 3      
           Constant -3.16* (1.20)    
           Age  0.02 (0.02) 0.98 1.02 1.06 
           Sex (Male vs Female) -0.85 (0.55) 0.15 0.43 1.27 
           SVR (No vs Yes) -1.17* (0.39) 0.15 0.31 0.66 
           OST (No vs Yes) 0.44 (0.45) 0.64 1.46 3.71 
           Cirrhosis (No vs Yes) 0.82 (0.44) 0.95 2.26 5.39 
           Treatment Regimen (DAA vs IFN) 0.37 (0.37) 0.70 1.45 2.98 




Table 9. Summary of logistic regression analyses for control variables (age, sex, SVR, OST, and cirrhosis), PCR status (Analysis 1), 
Treatment Engagement (Analysis 2), and Treatment Regimen (Analysis 3) predicting drug related death  
Note: *p < 0.05
  95% CI for Odds Ratio 
 B (SE) Lower Odds Ratio Upper 
Analysis 1     
           Constant -2.45 (0.57)    
           Age  0.00 (0.01) 0.98 1.00 1.03 
           Sex (Male vs Female) -0.36 (0.28) 0.40 0.70 1.20 
           PCR status (Negative vs Positive) 0.17 (0.26) 0.71 1.19 2.00 
           R2 (Cox & Snell)= .00     
Analysis 2      
           Constant -3.39* (0.81)    
           Age  -0.01 (0.02) 0.97 0.97 1.03 
           Sex (Male vs Female) -0.12 (0.33) 0.47 0.89 1.69 
           OST (No vs Yes) 0.33 (0.32) 0.74 1.39 2.58 
           Treatment Engagement (Engagers vs Non Engagers) -1.71* (0.37) 2.67 5.52 11.44 
           R2 (Cox & Snell)= .05     
Analysis 3      
           Constant -3.13* (1.57)    
           Age  -0.01 (0.03) 0.94 0.99 1.05 
           Sex (Male vs Female) -0.70 (0.65) 0.14 0.50 1.77 
           SVR (No vs Yes) -1.38* (0.46) 0.10 0.25 0.62 
           OST (No vs Yes) 1.45 (0.77) 0.94 4.05 19.35 
           Cirrhosis (No vs Yes) 0.10 (0.69) 0.29 1.12 4.30 
           Treatment Regimen (DAA vs IFN) 0.72 (0.48) 0.81 2.06 5.23 




Analysis 2- PCR Positive treatment engagers vs PCR Positive treatment non- engagers 
 
          A total of 2499 individuals who tested HCV PCR Positive were identified. Of these, 
267 treatment non- engaging controls and 650 treatment engaging cases met the 
inclusion criteria (see Figure 5), and were randomly matched by age group and sex, 
leading to 263 treatment non- engaging controls and 263 treatment engaging cases 
included in the study (successful matching was not possible for four controls).  
 
           Baseline characteristics of cases and controls are presented in Table 7. The 
majority of cases (96.6%) and controls (97.3%) were under the age of 65 years, and 
male (67.3%).  
 
            During the study’s follow up period, there were 141 deaths out of 527 
individuals who were PCR Positive; 23 (16.3%) deaths were in treatment engaging 
cases, and 118 (83.7%) were in treatment non- engaging controls. Of 141 deaths, 54 
were classified as drug related deaths; 10 (18.5%) were in cases, and 44 (81.5%) were 
in controls.  
 
             For all-cause mortality, the survival distributions for the two groups were 
significantly different, with non-engaging controls at a significantly higher risk of all-
cause mortality, χ2(2) = 91.395, p = <.001 (see Figure 6). The odds of all-cause mortality 
was 12.2 times higher amongst treatment non- engaging controls, (aOR 12.15, 95% CI 
7.03- 20.99, p < .001) compared to treatment engaging cases, after adjustment for age, 





          For drug related deaths, the survival distributions for the two groups were 
significantly different, with non-engaging controls at a significantly higher risk of drug 
related death, χ2 (2) = 32.364, p = <.001 (see Figure 7). The odds of a drug related death 
was 5.5 times higher amongst treatment non- engaging controls, (aOR 5.52, 95% CI 
2.67- 11.44, p < 0.001) compared to treatment engaging cases, after adjustment for 










































Figure 5. Selection of treatment engaging/interferon treated cases and treatment 
non- engaging/direct acting antiviral treated controls based on inclusion/exclusion 
criteria.    
2499 
Individuals testing PCR Positive 
 Potential Controls= Treatment Non- 
Engagers: 835 
 Potential Cases=Treatment 
Engagers: 1664 
799 
Following exclusion of individuals with 
other risk factors e.g. blood products, 




Following exclusion of individuals with 
other risk factors e.g. blood products, 




Following exclusion of individuals with 
postcodes out with Tayside (N= 97) 
 
1338 
Following exclusion of individuals with 
postcodes out with Tayside (N= 151) 
 
267 treatment non- engaging 
controls  
Following exclusion of individuals 
tested before 2008/tested after 
November 2017 (N= 435) 
 
934 
Following exclusion of individuals 
tested before 2008/tested after 
November 2017 (N= 404) 
 
692 
Following exclusion of individuals 
commencing treatment after 
November 2017 (N= 242) 
 
650 treatment engaging cases  
Following exclusion of individuals co-
infected with other blood borne 
viruses (N= 42) 
 
380 interferon 
treated cases  
270 direct 
acting antiviral 





Figure 6. Kaplan Meier survival curve for time from first antibody positive test to all-












Figure 7. Kaplan Meier survival curve for time from first antibody positive test to drug 












Analysis 3- Interferon treated vs DAA treated 
 
          A total of 1664 PCR Positive individuals who engaged with treatment were 
identified. Of these, 380 interferon treated cases and 270 direct acting antiviral treated 
controls met the inclusion criteria (see Figure 5), and were randomly matched by age 
group and sex, leading to 266 interferon treated cases and 266 direct acting antiviral 
treated controls included in the study (successful matching was not possible for four 
controls).  
 
          Baseline characteristics of cases and controls are presented in Table 7. The 
majority of cases (96.6%) and controls (97.3%) were under the age of 65 years, and 
male (67.3%).  
 
           During the study’s follow up period, there were 49 deaths out of 532 PCR 
Positive individuals who engaged with treatment; 35 (71.4%) deaths were in interferon 
treated cases, and 14 (28.6%) were in DAA treated controls. Of 49 deaths, 28 were 
classified as drug related deaths; 21 (75%) in cases, and 7 (25%) in controls.  
 
          Differences in length of follow up time between cases and controls were 
controlled for by implementing a limit of a maximum follow up period of 55 months 
after treatment commencement. This time parameter was decided upon as the first 
recorded date of treatment commencement in the DAA control group was 1st June 
2014, with a 55 months of follow up until the final day of follow up- 31st December 
2018. Accordingly, any deaths occurring after the established maximum follow up 




Consequently, 9 of the 35 deaths, and 3 of the 21 drug related deaths, occurring in 
cases were not included in the analysis.  
 
          For all-cause mortality, the survival distributions for the two groups were not 
significantly different, χ2(2) = .071, p =.789 (see Figure 8). No difference in risk of all-
cause mortality between DAA treated controls and interferon treated cases was 
detected (aOR 1.45, 95% CI 0.70- 2.98, p = .37), after adjustment for age, sex, SVR, OST, 
and cirrhosis (see Table 8). Note, 28 individuals were omitted from the regression 
analysis due to missing data on cirrhosis; 8 controls and 20 cases.  
 
          For drug related deaths, the survival distributions for the two groups were not 
significantly different, χ2(2) = .281, p =.596 (see Figure 9). No difference in risk of drug 
related death between DAA treated controls and interferon treated cases was detected 
(aOR 2.06, 95% CI 0.80- 5.23, p = .13), after adjustment for age, sex, SVR, OST, and 







Figure 8. Kaplan Meier survival curve for time from treatment commencement to all-
cause mortality comparing interferon treated cases and direct acting antiviral agent 












Figure 9. Kaplan Meier survival curve for time from treatment commencement to 
drug related death comparing interferon treated cases and direct acting antiviral 













          The aim of the project was to investigate whether HCV diagnosis and engagement 
with treatment services reduces all-cause mortality and drug related death, and 
whether any effect is dependent on treatment regimen and intensity of engagement 
with HCV treatment service staff. A series of retrospective case control studies were 
performed to answer three main research questions. 
 
          The first case control study compared PWID with active HCV infection (PCR 
Positive) vs PWID who had been HCV infected but cured spontaneously (PCR Negative) 
to answer the research question does HCV diagnosis reduce risk of mortality among 
PWID. We hypothesised that HCV diagnosis will reduce mortality outcomes among 
PWID. The only difference between cases and controls was the random biological 
event of spontaneous HCV cure; the two cohorts can be presumed to have behaved in 
the same way up to the point of being told their HCV status. Contrary to our 
hypothesis, our results suggest that awareness of HCV positive infection status makes 
no difference to mortality, either all cause or drug related. This finding is line with 
Spelman et al. (2015) who found no difference in post notification injecting behaviours 
when comparing PWID who received a positive test result to those who tested HCV 
negative. This highlights the need for greater communication by healthcare 
professionals to patients diagnosed of HCV of the importance of reducing injecting risk 
behaviours. 
 
          The second case control study compared PCR Positive patients who engaged vs 
did not engage with treatment services to answer the research question does 
engagement with HCV treatment services impact mortality outcomes of PWID. We 
hypothesised that engagement with HCV treatment services would reduce both risk of 




provide evidence that HCV treatment engagement is a significant protective factor 
against both all-cause mortality and drug related death amongst PWID, with non-
engaging PCR Positive individuals having 12 times higher odds of all-cause mortality 
and 5 times higher odds of drug related death, in comparison to PCR Positive 
treatment engaging persons. These findings confirm previous research that engaging in 
Hepatitis C treatment leads to a reduction in all-cause mortality (Tait et al., 2017). It 
could be argued that embarking on the HCV treatment process enables a “teachable 
moment” (TM) for patients; a concept first theorised by Hochbaum (1958) which 
describes health events which motivate individuals to adopt risk reducing health 
behaviours, with TMs already suggested in relation to sexual behaviours and HIV 
prevention (Fabiano, 1993). It is also possible that the event of achieving SVR may also 
be a teachable moment. It is important to note that our cohort was selected from a 
population that has high testing, diagnosis, and treatment rates, nearly reaching WHO 
2030 targets. Therefore, there is minimal selection bias in our cohorts.  
 
         The final case control study endeavoured to explore further if there was any effect 
of treatment engagement by comparing the mortality outcomes of intensive 
interaction with health care in interferon treated patients vs DAA treated patients, who 
have much shorter and less intense engagement. We hypothesised that engagement 
with interferon based treatment regimens would result in a greater reduction in risk of 
all-cause mortality and drug related death than engagement with DAA based 
treatment regimens. The result clearly shows no difference, suggesting that the 
benefits of treatment engagement are associated with the act of engaging with 
treatment rather than the treatment regime itself. The comparability of these two 
treatment groups must be scrutinised due to, for example, considerable differences in 
treatment experiences and the availability of illicit drugs during the respective periods 
when these patients were treated. However, eligibility for inclusion in the study cohort 
began from 2008, as the introduction of the MCN for HCV care took place in 2008. 




Nonetheless, other factors such as changes in the type of illicit drugs available, 
naloxone programmes, austerity, the increasing age of PWID in Tayside, and poly drug 
use behaviours may also contribute to DRD rates over the study period of 2008 to 
2017. These unmeasured potential confounding variables could contribute to the 
association between treatment engagement and risk of mortality amongst the study 
cohort.  
 
         It could be argued that patients engaging with HCV treatment services are self-
selecting individuals who are more willing to engage with services in general, and that 
we have observed a generalised engagement effect, rather than a specific HCV 
treatment effect. Furthermore, it could be proposed that people are engaging with 
treatment at a time of declining risk due to experiencing greater stability when 
compared to treatment non-engagers. It is not clear if non-engaging behaviour is 
amenable to change or improved prognosis.  
 
           This finding also has significant implications for addressing ongoing concern 
around the change in intensity of staff contact when transitioning from the interferon 
era to the DAA era of treatment. DAA treated patients are arguably more unstable than 
interferon treated patients as many would have been deemed to be unsuitable for 
interferon therapy due to associated adverse side effects. Indeed, it has been 
hypothesised that DAA treated patients might have worse outcomes than interferon 
treated patients given the less intensive support during therapy. Thus, the fact that we 
observed no difference in risk of all-cause mortality or drug related deaths between 
the two groups is evidence that intensity of staff engagement is not an important 
protective factor. Consequently, current treatment practice does not need to 
implement an increase in intensity of staff contact. Future research is needed to 
elucidate whether intensive staff contact is protective against other important 





         Congruent with prior research, the current study found that achieving SVR is a 
protective factor against all-cause mortality and drug related death (Innes et al., 2015; 
Cacoub, Desbois, Comarmond, Saadoun, 2018; Backus, Belperio, Shahoumian, & Mole, 
2018; Ioannou & Feld, 2019). It has been posited that achieving SVR is a psychologically 
positive experience for patients due to the subjective feeling of achievement this 
brings, providing motivation to reduce injecting risk behaviours. Hence, it is interesting 
that in our study, patients treated with DAA therapies do not have better outcomes 





         The predominant limitation of the current study was the retrospective study 
design, with substantial limitations in quality of available data. Data on a number of 
meaningful variables was not available. For instance, OST data was not attainable for 
PCR Negative individuals, and therefore could not be included as a predictor variable in 
the regression model in analysis 1. Moreover, available OST data indicated whether 
individuals were on OST at the time of diagnosis, but not whether they were on OST at 
the time of their death, which could have given more insights. Data on history of non-
fatal overdoses would also have been advantageous, as previous research has 
demonstrated that non-fatal overdose is classified as a risk factor for ensuing fatal 
overdose in PWID (Caudarella et al., 2016). Other unattainable data which could have 
been beneficial were injecting history, injecting status, change in injecting behaviours 
and other significant comorbidities. Furthermore, data on unmeasured potential 
confounding variables, such as homelessness and mental health problems, which may 




with further research needed to elucidate the complex reasons that lead to non-
engagement.   
 
           Another limitation to the current study is the lack of differentiation of individuals 
in analysis 2 (Treatment Engagers vs Non-Engagers). Specifically, engagers were not 
differentiated by a more specific measurement of treatment engagement e.g. how 
many weeks of treatment they completed and/or whether they completed their full 
course of treatment. Equivalently, non-engagers were not differentiated by the reason 
for their non-engagement. For instance, a minority of patients may have not started 
treatment due to concerns around treatment contra-indications or age. This is 
particularly relevant for patients treated in the interferon treatment era due to higher 
incidence of associated adverse side effects compared to DAA based treatment 
regimens. Arguably such differentiation may provide greater insight into the impact of 
treatment engagement on subsequent risk of death, and whether, for example, 
completion of treatment potentiates the engagement effect. Likewise, in analysis 3 
(Interferon vs DAA patients), we did not differentiate between treatment experienced 
and treatment naïve patients. Such differentiation may provide understanding as to 
whether previous treatment experience, and specifically treatment with interferon 





          Although our study has several limitations, a range of strengths can be identified 
mainly regarding the location of the study. Specifically, Tayside is uniquely placed to 
perform this type of study as all HCV testing in Tayside is carried out by the National 




local clinical database. All services work through central laboratories which perform all 
HCV related testing and relay these results to the Hepatitis Specialist Service who 
record them in the clinical database. Moreover, NHS Tayside has a HCV testing and 
treatment service with a decentralised, person focussed approach which has led to 
over 90% of the prevalent population being diagnosed and over 80% of those 
diagnosed treated. Coupled with the aforementioned unique data capture, we believe 
that these strengths minimise biases that could impact on conclusions and have 





           In conclusion, a series of case control studies were conducted to investigate the 
impact of HCV diagnosis and engagement in treatment services on risk of all-cause 
mortality and drug related death among PWID. No difference in risk of all-cause 
mortality or drug related death was observed between PWID with active HCV infection 
(PCR Positive) and HCV infected but cured spontaneously (PCR Negative). HCV 
treatment engagement is significantly protective against all-cause mortality and drug 
related death, with non- engaging PCR Positive individuals 12 times higher odds of all-
cause mortality and 5 times higher odds of drug related death, in comparison to PCR 
Positive treatment engaging persons. This engagement effect is independent of 
treatment regimen, with no difference in risk of all-cause mortality or drug related 
death between interferon treated patients and DAA treated patients, suggesting 
intensity of engagement with staff is not an important factor. These findings provide 
further evidence of the importance of HCV diagnosis and treatment engagement 





4. General Discussion 
 
          The current project aimed to investigate the impact of HCV treatment on 
injecting risk behaviours and mortality outcomes of PWID. Our systematic review 
focused upon reviewing all available literature on the impact of HCV treatment on 
behavioural change in relation to drug use, including injecting behaviour and injecting 
equipment sharing. This review revealed a lack of published literature in this important 
research area, with varying study designs and interventions. Consequently, drawing 
conclusions around whether treatment engagement beneficially changes patients’ 
injecting risk behaviours is challenging. Moreover, it is clear that additional research is 
required to explore this research question in the new DAA era of HCV treatment. 
However, after examination of the available research, results of our review suggest 
that treatment engagement positively impacts clients’ injecting drug use and injection 
equipment sharing behaviour.  
 
           These findings, coupled with previous work conducted by our group, which 
suggested that improved access to HCV care leads to greater engagement with 
healthcare services and substantially reduced risk of all-cause mortality, provided a 
sound basis to conduct several case control studies, investigating the impact of HCV 
treatment on mortality outcomes of PWID. Specifically, we aimed to investigate 
whether HCV diagnosis and treatment reduce risk of all-cause mortality and drug 
related death among PWID, and whether any change is dependent on treatment 
regimen and intensity of engagement with staff. Results showed that HCV diagnosis did 
not impact mortality outcomes. However, it was found that HCV treatment 
engagement is significantly protective against both all-cause mortality and drug related 





            Overall, the current project provides strong evidence of the importance of 
universal HCV testing and treatment accessibility, with widening access to treatment 
instrumental in lowering patients’ risk of mortality. It is crucial that every effort is made 
by service providers to encourage HCV positive individuals to initiate treatment, 
emphasising the importance of ongoing engagement during their treatment process 
and the prioritisation of reducing injecting risk behaviours. At a systemic level, it is vital 
that an aggressive and sustained effort is made to minimise barriers and stigma 
relating to treatment access for PWID to facilitate HCV diagnosis and linkage to care. 
Treatment providers should be encouraged to ensure patients feel supported and 
respected, rather than stigmatised, and be active agents in their healthcare. With 
Tayside demonstrating high testing, diagnosis and treatment rates, it is imperative that 
a person- focussed approach to HCV care is continued in order to reach individuals who 
have not yet successfully engaged with treatment services, with the possibility of the 
creation of individualised pathways of care in order to engage “hard to reach” patients.  
 
Directions for future research 
 
          While the current project highlights that engagement in HCV treatment is 
significantly protective against drug related death and all-cause mortality among PWID, 
further investigation is required to evaluate the underlying mechanisms of this 
engagement effect and how HCV treatment engagement facilitates behaviour change. 
Future qualitative research could be used to explore psychosocial differences in HCV 
treatment engagers and non-engagers to understand the factors that prevent people 
living with HCV engaging in testing and treatment. For example, it would be beneficial 
to examine the differing attitudes and emotional responses to HCV infection, health 
status and interpretation of illness between those who engage and those who are 
reluctant to engage, and whether an individual’s peer network has an influence on this. 




development of a co-designed intervention that increases the reach, accessibility, and 
effectiveness of HCV care, improving treatment pathways in pursuit of the WHO goal of 
elimination. This would require multifaceted input from people living with HCV, 
referring staff and service providers to adapt current testing and treatment pathways 
to incorporate stakeholder preferences. Furthermore, future research should focus on 
promotion of HCV care and engagement strategies, highlighting the psychological, 
social and physical health benefits of achieving a cure, as well as treatment options. 
          
         Other directions for future research may be to investigate whether patients who 
engage with different specialised treatment pathways (e.g. hospital outpatient clinic, 
drug treatment outreach clinic, community pharmacy outreach) have differing 
mortality risk, again allowing for greater insight into the complex mechanisms 
underlying this engagement effect, and how treatment pathways can be improved to 
promote engagement. Future research may also seek to further investigate the 
engagement effect by employing varying measurements of engagement such as 
attendance of appointments during the treatment process. By measuring engagement 
in such a way, this could act as a proxy for intensity of staff contact, and allow for 
additional investigation into whether the engagement effect is dependent on intensity 
of staff interaction.  
 
         Lastly, future research may seek to investigate whether sense of achievement 
through achieving SVR has an impact on behaviour change in relation to patients’ 
injecting behaviours. This could be prospectively accomplished by measuring patients’ 
subjective sense of achievement at time of SVR, along with measurements of injecting 
risk behaviours before and after. Alternatively, mortality outcomes of DAA treated 
patients who completed their course of treatment could be analysed by comparing 






           
                   Pressingly, there is need for greater collaboration between specialist 
substance misuse services and HCV treatment services to operate in an integrated 
structure to tackle the observed rising trends in drug related deaths. Services should be 
encouraged to implement a person centred, public health approach in their delivery of 
care. This is in line with the Scottish Government’s National Drug and Alcohol Strategy 
which encourages the addressing of patients’ complex needs, such as treating both 
their HCV infection and their problematic drug use (Population Health Directorate, 
Scottish Government, 2018). It is imperative to ensure that all services are equipped 
with adequate levels of resources and staffing to assess, manage and treat both 
patients’ Hepatitis C and problematic drug use successfully. Furthermore, engagement 
in HCV care may provide an opportune time to implement targeted psychosocial 
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A B S T R A C T
Background: A systematic review was conducted to determine the impact of Hepatitis C (HCV) treatment on
substance use behaviour in people who inject drugs (PWID).
Methods: A search for peer reviewed journal articles from 1991 to present day was conducted using the
following databases: PubMed, EMBASE, CINAHL and PsycINFO. Studies were appraised against the following
inclusion criteria: recruitment of PWID for HCV treatment (either interferon alpha or direct acting antivirals
based); measurement of behavioural change in relation to drug use; studies published in English.
Results: Five studies investigating the impact of HCV treatment on behavioural change in relation to drug use
amongst PWID were identified. Studies investigated the impact of HCV treatment on past month injecting drug
use (four studies), injecting frequency (two studies), needle and syringe borrowing (two studies) and injecting
equipment sharing (three studies). Three of the four studies assessing impact of treatment on past month in-
jecting frequency found treatment significantly reduced the odds of participants reporting past month injecting
at follow up. One study found that there was significant reduction in weekly injecting frequency between en-
rolment, treatment and follow up. No association was found between treatment engagement and needle and
syringe borrowing. Two out of three studies reported a significant decrease in injecting equipment sharing
between enrolment, treatment and follow up.
Conclusions: Comparison and synthesis of results was challenging due to heterogeneity between studies.
Moreover, four out of the five selected studies were conducted during the interferon era of treatment, possibly
limiting the generalisability of the current review’s results to the new DAA treatment era. However, it is likely
that engaging in treatment has a positive impact upon patients’ injecting drug use and injection equipment
sharing behaviour. This raises the possibility that this may be an opportune time for further harm reduction
measures.
Introduction
Hepatitis C (HCV) is a blood borne virus which affects around 71
million people globally (Blach et al., 2017; World Health Organisation,
2017). It is estimated that 39.2% of PWID are currently living with HCV
infection worldwide (Grebely et al., 2019). HCV infection is a major
contributor to morbidity and mortality among this population
(Stanaway et al., 2016). Research has supported the treatment of active
drug users for Hepatitis C, demonstrating successful adherence to
treatment and favourable sustained viral response rates (Hajarizadeh
et al., 2018). This highlights the feasibility and effectiveness of scaling
up treatment services to reduce the prevalence of the disease, using
“treatment as prevention” (TasP) models of elimination (E. J. Aspinall
et al., 2013; Fraser et al., 2018). TasP models of elimination focus on
treating PWID for HCV as they are the most at- risk population for
acquiring the virus. Therefore, HCV elimination can be achieved by
treating those at risk of continuous HCV transmission (Hellard, Doyle,
Sacks‐Davis, Thompson, & McBryde, 2014; Hellard et al., 2015;
Hutchinson et al., 2015). However, testing, diagnosis and treatment
rates of HCV infection among PWID have found to be inadequate in
some settings, despite evidence that the incidence of HCV- related liver
disease is on the rise (Socías et al., 2019; Thrift, El-Serag, & Kanwal,
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2017; Wiessing et al., 2014). Barriers to testing and treatment are
complex, but include concerns among providers around ongoing risk
behaviour, such as ongoing substance misuse, and the sharing of in-
jecting paraphernalia; risk of reinfection; the worsening of psychiatric
comorbidities; and poor treatment adherence (Grebely & Tyndall,
2011).
In spite of these barriers to treatment, there is a suggestion that the
benefits of engaging with HCV care stretch beyond liver morbidity
outcomes. Studies report the positive impact of HCV status notification
on reduction in drug use among PWID (E. Aspinall et al., 2014; Bruneau
et al., 2013). PWID accessing HCV treatment have the opportunity to
develop a therapeutic relationship with healthcare professionals in-
volved in their care, which may facilitate behavioural change (Spelman
et al., 2015).
Understanding the influence of treatment receipt on behaviour in
relation to drug use in PWID may have an effect on treatment acces-
sibility for this population, and may facilitate the development of
supplementary support services to be offered with treatment. The ob-
jective of this review was to examine the literature investigating how, if
at all, the behaviour of PWID changes in relation to drug use when
undergoing HCV treatment and during follow up, including changes in
injecting behaviour, injecting frequency, needle and/or syringe bor-
rowing, and injecting equipment sharing.
Methods
This systematic review was conducted and reported in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (Moher, Liberati, Tetzlaff, & Altman,
2009). The study was registered in PROSPERO (CRD42018116625).
Search strategy
The International Prospective Register of Systematic Reviews
(PROSPERO) was searched to confirm no similar review had already
been conducted. A search for peer reviewed journal articles was con-
ducted using PubMed, EMBASE, CINAHL and PsycINFO, on 9th
November 2018. A grey literature search of the International Network
on Hepatitis in Substance Users (INHSU) conference abstracts was also
conducted. This symposium was specifically targeted as it is dedicated
to research focusing on Hepatitis C in the cohort of interest, namely
PWID. A time parameter was implemented for studies conducted from
1991 to 2018, as 1991 was the year interferon became commercially
available for treatment of Hepatitis C. An inclusive list of search terms
in line with each search topic was generated to develop an effective
search strategy. Both keywords and indexed subject headings (MeSH
and EMTREE terms) were included in the formulation of search strings
for each database search. Search topics included “Hepatitis C treat-
ment”, “behaviour change” and “drug use”. Table 1 includes a full list of
search terms utilised in the search strategy, grouped by search topic.
Manual searches of reference lists of selected studies were also con-
ducted. Searches were limited to studies published in English.
Study selection
Fig. 1 shows a PRISMA flowchart of the selection process. Screening
of the search strategy results was conducted by two reviewers. The first
phase involved importing all citations into EndNote X8 and removing
duplicate records. Titles were screened, and irrelevant records re-
moved. Abstracts were then assessed using the inclusion and exclusion
criteria (see Table 2). All remaining records were then subjected to a
full text evaluation for eligibility.
Data extraction and synthesis
Data from selected studies was extracted using a piloted data ex-
traction form by one reviewer (MC). The following variables were
collected: first author, title, publication year, full paper or abstract,
primary aim, study design, location, setting, total study duration, follow
up period, sample characteristics, sample size, intervention, outcome/
measure of behaviour change, main results, conclusions. The authors of
Malaguti et al. (2019) were contacted for clarification regarding follow
up period in their study. The authors of Artenie et al. (2019) were
contacted to obtain updated data, and they kindly provided an un-
published manuscript relating to their INHSU conference abstract. The
data synthesis used a ESRC style quantitative narrative synthesis (Popay
et al., 2006). This was used as there was too much heterogeneity be-
tween selected studies for meta- analysis.
Quality appraisal
Risk of bias in individual studies was assessed using the Quality
Appraisal Checklist for quantitative intervention studies by NICE public
health guidance (National Institute for Health & Care Excellence, 2012).
The checklist enables both the evaluation of the study’s internal and
external validity, addressing aspects of study design such as participant
characteristics, definition of and allocation to intervention/control
conditions, and methods of analyses. Each study was awarded separate
overall quality ratings for internal and external validity, with ratings
ranging from 1 to 3. Quality appraisal for four studies was in-
dependently conducted by two reviewers (MC and AM), with dis-
crepancies in ratings resolved by discussion until consensus was met. A
Cohen’s kappa coefficient (κ) was calculated to assess inter-rater
agreement, κ= .61, p < .001. This kappa (κ) value represents a sub-
stantial agreement (Landis & Koch, 1977). A third reviewer (ER), along
with the first reviewer (MC), conducted a quality appraisal for the fifth
study. This was necessary to reduce bias as the second reviewer (AM)
was an author of the study. A Cohen’s kappa coefficient (κ) was cal-
culated to assess inter-rater agreement, κ= .68, p < .001, representing
a substantial agreement (Landis & Koch, 1977).
Results
Search results
The database search produced a total number of 863 records. After
removing duplicates (n=141), a further 702 were removed after title
and abstract screening. Twenty- one full text articles were assessed for
eligibility, 16 were removed with reasons, leading to the final inclusion
of 5 studies (see Fig. 1).
Characteristics of selected studies
Characteristics and findings of selected studies are summarised in
Table 3. Studies evaluated impact of treatment on drug use by re-
cruiting participants from a number of settings including tertiary hos-
pitals; GP and primary care clinics; community clinics; drug and alcohol
treatment clinics; private medical practices; and injecting equipment
provision services. There were four prospective cohort studies and one
Table 1
Keyword search terms utilised in search strategy, grouped by search topic.
Hepatitis C treatment Behaviour change Drug use
Hepatitis C treatment/therapya Behavi* change Drug abuse
Interferon-alpha/ therapeutic usea Behavi* benefit Drug misuse
Drug use change* Drug use
Inject behavi* Drug disorder
Risk behavi* Drug addict*
Inject* frequency Drug dependen*
Drug intravenous*
a MeSH/EMTREE terms.
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retrospective cohort study. Two studies included comparison groups in
their study design. Alavi et al. (2015) utilised PWID that did not receive
treatment as their comparison group. Artenie et al. (2017) utilised three
comparisons groups, namely PWID who did not engage in treatment
post- diagnosis; PWID who did not engage in treatment due to spon-
taneous clearance of the virus; and HCV positive PWID who were not
eligible for treatment due to contra-indications.
Four studies investigated past month injecting drug use; two studies
investigated injecting frequency; two studies investigated needle and
syringe borrowing; and three studies investigated ancillary injecting
equipment sharing. Of the five studies selected, four studies involved
treatment with pegylated interferon alpha and/or ribavirin, with only
one study involving treatment with direct acting antivirals (DAAs).
Follow up periods ranged from 24 weeks to 2 years. In the sampled
studies, the majority of participants were Caucasian males, with a mean
age ranging from 32 to 47 years old, who had injected drugs in the last
6 months prior to study enrolment. Two of the five selected studies
solely recruited participants with acute HCV infection (Alavi et al.,
2015; Artenie et al., 2017). Recruiting patients for treatment with acute
HCV infection is not reflective of standard clinical practice, as these
patients have a 20–30% of spontaneous clearance during the acute
phase of the infection, making treatment uneconomical at this stage
(Aisyah, Shallcross, Hully, O’Brien, & Hayward, 2018). However, effect
on injecting behaviour may still be relevant.
Risk of bias in individual studies
Table 4 provides detailed quality appraisal scores for each included
study. The results of the scoring process suggests that Artenie et al.
(2017) was the methodologically most robust study. Overall, the se-
lected studies scored very highly on external validity. However, several
issues of internal validity can be discussed. For instance, the occurrence
of losses to follow up may have caused selection bias in several studies,
with sizeable differences in socio-demographic characteristics between
Fig. 1. Search Strategy.
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participants who remained, versus lost to follow up. For example,
Midgard et al. (2017) found that participants who remained in 12
weeks follow up were more likely to be employed, have higher edu-
cation levels, had less history of incarceration, and had injected more
often in the last month, in comparison to those lost to follow up.
Therefore, it is possible that those remaining in follow up were more
likely, for instance, to have greater access to social support, impacting
on their ability to engage in treatment and facilitate behavioural
changes in relation to their drug use. Another issue of internal validity
is the lack of comparison groups in some studies, e.g. Artenie et al.
(2019) and Midgard et al. (2017), making it challenging to attribute
behavioural changes to the intervention, i.e. HCV treatment. A final
point to note is the quality assessment tool’s appraisal of the outcome
variable’s reliability. According to the Quality Appraisal Checklist’s
guidelines, outcome variables that are measured subjectively, e.g. self
report, are to be scored poorly and could introduce information bias
(National Institute for Health & Care Excellence, 2012). As all selected
studies utilised a self-reported measure of injecting risk behaviours,
they were all poorly scored for this part of the appraisal process.
However, research has demonstrated that self-reported drug use among
PWID is reliable and valid (Darke, 1998). Therefore, it is the opinion of
the authors that the selected studies rate more highly for study design
appraisal.
Results of individual studies
Impact of treatment on past month injecting drug use
Four studies investigated the impact of treatment on past month
injecting drug use at various time points during treatment and follow
up, assessed dichotomously (Alavi et al., 2015; Artenie et al., 2017;
Artenie et al., 2019; Midgard et al., 2017). Alavi et al. (2015) reported
no association between HCV treatment and past month drug use during
24 weeks follow up, when comparing PWID who did and did not receive
treatment (aOR 1.06, 95% CI 0.93–1.21, n=124). However, this study
did not differentiate between participants based on their reasons for not
engaging in treatment after study enrolment, possibly explaining the
non-significant results of the study as untreated participants are argu-
ably a more heterogeneous cohort. A second study by Artenie et al.
(2017) did make this distinction, evaluating the impact of treatment on
injecting drug use at one year follow up when comparing people who
received treatment, and three comparison groups: people who sponta-
neously cleared the virus and did not require treatment; people who
were not eligible for treatment due to contra-indications to therapy; and
people who voluntarily chose not to engage in HCV care. Results
showed that the received treatment group were less likely to report
drug use at follow up in comparison to the voluntary non- engagement
group (aOR 0.18, 95% CI 0.04- 0.76, n=87). The odds of reporting
drug use at follow up amongst the spontaneous clearance (aOR 0.34,
95% CI 0.08–1.40, n= 87) and contra- indications to therapy groups
(aOR 0.24, 95% CI 0.05–1.22, n=87), were not significantly lower in
comparison to the voluntary non- engagement group. This finding is
supported by Midgard et al. (2017) who found that there was a sig-
nificant reduction in any past month injecting drug use during treat-
ment and 12 week follow up (OR 0.89, 95% CI 0.83– 0.95, n=93),
with the likelihood of injecting halved at treatment completion com-
pared to study enrolment. A fourth study evaluated the impact of DAA
based treatment on past month injecting drug use and found that there
was an overall significant reduction in opioid injecting (OR: 0.95, 95%
CI 0.92- 0.99, n= 190) between treatment initiation and 2 year follow
up (Artenie et al., 2019). However, no reduction in stimulant (cocaine
and amphetamine) injecting was reported (OR 0.98, 95% CI 0.94–1.02,
n=190).
Impact of treatment on injecting frequency
Two studies investigated the impact of treatment on injecting fre-
quency. Midgard et al. (2017) measured≥ daily injecting as a proxy for
past month injecting frequency, and found that the proportion of par-
ticipants who reported≥ daily injecting did not significantly change
during treatment and follow up (OR 0.98, 95% Cl 0.89–1.07, n= 93). It
is notable that injection risk behaviours amongst participants in this
study were low at baseline, with only 28% of participants who achieved
12 weeks follow up reporting≥ daily injecting at enrolment. Moreover,
the authors mention a lack of statistical power due to the relatively
small sample size, providing a second explanation of lack of significant
findings. A second study by Malaguti et al. (2019) investigated changes
in weekly injecting frequency between enrolment, during treatment and
at 6 months follow up. Results showed a significant decrease in in-
jecting frequency between enrolment and future time points (χ2
(7)= 36.44, p < .001, n= 32), with the largest reduction in injecting
reported between enrolment and week 8 of treatment, maintained
through to 6 months follow up. A criticism of this study may be the high
degree of incomplete data, with only 38% of participants providing
data for all time points.
Impact of treatment on needle and syringe borrowing
The impact of treatment on needle and syringe borrowing was in-
vestigated by two studies. One such study by Alavi et al. (2015) found
that treatment was not associated with a reduction in needle and syr-
inge borrowing during follow up, when comparing PWID who did and
did not receive treatment (aOR 0.99, 95% CI 0.89, 1.07, n=124). A
second study found that treatment receipt did not significantly facilitate
a reduction in use of non-sterile needles (OR 0.94; 95% CI 0.79–1.12,
n=93) (Midgard et al., 2017).
Impact of treatment on injecting equipment sharing
Facilitation of a reduction in injecting equipment sharing by treat-
ment was explored in three studies. One study reported a significant
decrease in injecting equipment sharing, including mixing container,
filter and water, during treatment and 24 weeks follow up (aOR 0.85,
95% CI 0.74- 0.99, n=124), with a reduction in the number of par-
ticipants reporting sharing from 54% at baseline to 17% at follow up
(Alavi et al., 2015). In contrast Midgard et al. (2017) reported no as-
sociation between treatment and injecting equipment sharing, in-
cluding spoons, mixing containers, drug solution, water and filter,
during treatment and 12 week follow up (OR 0.87, 95% CI 0.70–1.07,
n=93). One study investigating the impact of DAA based treatment on
behavioural outcomes reported a significant reduction in the number of
participants reporting needle and syringe sharing during treatment and
2 year follow up (OR 0.87, 95% CI 0.80- 0.94, n= 190) (Artenie et al.,
2019). However, it must be noted that although a reduction in needle




Participants: people who inject drugs (PWID).
Study intervention: Hepatitis C diagnosis and treatment (either interferon alpha
or direct acting antivirals based).
Comparators: participants themselves i.e. behaviour measured before and after
treatment; or PWID who did not receive treatment; or PWID who chose to not
engage in treatment post HCV diagnosis.
Primary outcome: behavioural change in relation to drug use e.g. injecting
behaviour, needle and syringe borrowing, sharing of ancillary equipment.
Studies published in English, utilising a quantitative or mixed- methods study
design.
Exclusion Criteria
Studies utilising a purely qualitative study design; individual case studies.
Studies that are entirely theoretical.
Participants who are non- injecting patients, or PWID who were treated for other
blood borne viruses.
Studies investigating the impact of Hepatitis C treatment in prison populations.
Studies focusing on the impact of knowledge of HCV status, and not HCV
treatment, on behavioural change in relation to drug use.
Studies focusing on reinfection rates after treatment.
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prevalence of this risk behaviour was low at only 16% of the 62% of
participants who reported past month injecting.
Discussion
Summary of evidence
In spite of the concerns around diagnosing and treating PWID for
Hepatitis C, there is a dearth of research on the impact of engaging in
treatment on behavioural change in relation to drug use in this popu-
lation. The current review only identified five studies which directly
measured behavioural change outcomes in PWID engaged in treatment.
As a consequence of the limited number of studies identified, and
variations in follow up times, behavioural outcomes, and treatment
interventions, drawing conclusions around whether treatment engage-
ment is effective in reducing drug use and injecting risk behaviours is
problematic.
The most common outcome measure of behaviour change in rela-
tion to drug use in the selected studies was past month injecting drug
use. Three of the four studies assessing this outcome found treatment
significantly reduced the odds of participants reporting past month
injecting at follow up (Artenie et al., 2017; Artenie et al., 2019; Midgard
et al., 2017). However, due to variations in study design, comparing the
findings of these separate studies is challenging. Accordingly, com-
bining the data on these results to conduct a meta- analysis was deemed
inappropriate. Additionally, it can be argued that dichotomously mea-
suring past month injecting drug use is limiting in regards to providing
insight into the impact of treatment on injecting behaviours. Combined
with infrequent measurements of drug use, it could be suggested that
the results of these studies simply reflect natural fluctuations in in-
jecting frequency among PWID, and do not accurately reflect a reduc-
tion in drug use. However, taken together, these findings suggest that
engaging in treatment may result in a possible reduction in injecting.
This challenges critics who believe that treating PWID for Hepatitis C is
not feasible due to concerns around treatment causing an increase in
injecting risk behaviours (Schaefer, Sarkar, & Diez-Quevedo, 2013).
Moreover, these findings support the notion that treatment engagement
may lower the risk of HCV transmission within the PWID population,
providing support for accessibility to treatment.
In regards to impact of treatment on other behavioural changes
related to drug use, findings are more inconsistent. For instance, of the
two studies which investigated the impact of treatment on injecting
frequency, only one study observed a significant decline in injecting
frequency between enrolment, treatment, and follow up (Malaguti
et al., 2019). Nonetheless, comparing the findings of these studies is not
suitable due to the contrasting measurements of injecting frequency;
namely weekly injecting, measured as a continuous variable (Malaguti
et al., 2019), and≥ daily injecting, measured as a binary variable
(Midgard et al., 2017).
Both studies investigating change in needle and syringe borrowing
found no association between treatment engagement and reduction in
these risk behaviours (Alavi et al., 2015; Midgard et al., 2017). Al-
though no significant decline was observed in either study, the fact that
such risk behaviours remain stable throughout treatment and follow up
has meaningful implications for risk of reinfection and onward trans-
mission. The minimisation of injecting risk behaviours after treatment
is critical to optimise patients’ chances of achieving sustained viral
responses and to reduce HCV prevalence at a population level
(Hickman, De Angelis, Vickerman, Hutchinson, & Martin, 2015). Of the
three studies investigating the impact of treatment on injecting equip-
ment sharing, two studies reported significant decreases in such beha-
viour between enrolment, treatment and follow up. However, of these
two studies, one study by Artenie et al. (2019) was conducted during
the DAA era of treatment, making the findings of this study in-
comparable to the other studies investigating this behaviour change.
Limitations of review
The predominant limitation of the current review was the number of
studies that met the inclusion criteria and the lack of comparability
between studies. As a consequence, a meta- analysis of findings was not
possible. Therefore, future reviews may seek to employ a more broadly
inclusive eligibility criterion, including, for example, the inclusion of
purely qualitative studies. Moreover, it is clear that future research
should focus on the reasons why engaging in treatment facilitates a
possible behavioural change in relation to drug use. A major limitation
Table 4
Quality appraisal ratings for each included study.
Alavi et al. (2015) Artenie et al. (2017) Malaguti et al. (2019) Midgard et al. (2017) Artenie et al. (2019)
1.1 Description of source population 3 3 3 3 1
1.2 Representativeness of eligible population 3 3 3 3 2
1.3 Representativeness of selected participants 2 3 2 2 2
2.1 Allocation to intervention or comparison NA NA NA NA NA
2.2 Description of intervention and comparison 3 3 2 3 2
2.3 Concealment of allocation NA NA NA NA NA
2.4 Blinding to exposure/comparison NA NA NA NA NA
2.5 Adequacy of exposure to intervention/comparison NA NA NA NA NA
2.6 Contamination NA NA NA NA NA
2.7 Similarity of other interventions to groups 3 3 NA NA NA
2.8 Lost to follow up 1 2 2 2 1
2.9 Setting reflects usual UK practice 2 2 3 3 2
2.10 Intervention reflects usual UK practice 2 2 3 3 2
3.1 Reliability of outcome measures 1 1 1 1 1
3.2 Completion of outcome measures 3 3 3 3 3
3.3 Assessment of important outcomes NA NA NA NA NA
3.4 Relevance of outcomes 3 3 3 3 3
3.5 Similarity of follow up times across groups NA NA NA NA NA
3.6 Meaningfulness of follow up times 3 3 3 3 3
4.1 Similarity of groups at baseline 3 3 NA NA NA
4.2 Intention to treat (ITT) analysis NA NA NA NA NA
4.3 Study’s power to detect an intervention effect 2 2 2 2 2
4.4 Estimates of effect size 3 3 3 3 3
4.5 Appropriateness of analytical methods 3 3 3 3 2
4.6 Precision of intervention effects 3 3 3 3 3
5.1 Internal validity 2 3 2 2 2
5.2 External validity 3 3 3 3 3
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of the review was that four of the five selected studies were conducted
during the interferon era of treatment. In particular, the characteristics
of people undergoing interferon treatment may potentially be different
to those undergoing DAA treatment. For example, those treated using
interferon based therapy may have experienced more adverse treatment
consequences, such as associated psychiatric conditions, in comparison
to those treated using the DAA based therapy. Moreover, the reasons
why engaging in treatment facilitates a positive behaviour change in
relation to drug may be disparate between the aforementioned treat-
ment groups. Consequently, the results of the current review may not
give insight into the impact of treatment on injecting risk behaviours in
the new DAA based treatment era, with future research clearly needed
to clarify this issue. Also, the review was hindered by the inclusion of
studies with selection bias of participants. All five studies involved
clinical trial participants, who were arguably more willing to engage in
treatment than the source PWID population. This was characterised by
relatively low lost to follow rates in some studies. Thus, the results of
the included studies may not be representative of the wider population
of PWID engaging in treatment.
Conclusions
Five studies investigating the impact of HCV treatment on beha-
vioural change in relation to drug use amongst PWID were identified.
The most common measure of behaviour change in relation to drug use
was past month injecting drug use, with three out of four studies re-
porting treatment significantly reduced the odds of participants re-
porting past month injecting at follow up. Studies also reported sig-
nificant reductions in injection equipment sharing between enrolment,
treatment and follow up; no significant changes in needle and syringe
borrowing; and varying results in regards to impact of treatment on
injecting frequency. Comparison and synthesis of results was challen-
ging due to heterogeneity of follow up times, treatment interventions,
and measures of behavioural outcomes. For future research, it would be
optimal for the research community to report injecting risk behaviour
in a standardised manner to enable comparison and strengthen con-
clusions of published literature. Four out of the five selected studies
were conducted during the interferon era of treatment, possibly limiting
the generalisability of the current review’s results to the new DAA
treatment era. However, results suggest the benefits of engaging in HCV
care stretch beyond liver morbidity outcomes, with treatment positively
impacting on patients’ injecting drug use and injection equipment
sharing behaviour. These findings have relevance to the “treatment as
prevention” model of Hepatitis C care, risk of reinfection and onward
HCV transmission (Fraser et al., 2018; Schulkind et al., 2018).
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Abstract
There is emerging evidence that Hepatitis C (HCV) treatment engagement is associ-
ated with change in drug behaviours and reduced drug-related death rates among 
people who inject drugs (PWID). The project aims to investigate whether HCV diag-
nosis and treatment engagement reduces all-cause mortality and drug-related death, 
and whether any effect is dependent on treatment regimen and intensity of engage-
ment with staff. Case-control studies comparing: PWID with active HCV infection 
(PCR positive) to PWID HCV infected but spontaneously resolved (PCR negative); 
PCR-positive patients who engaged with treatment services to nonengagers; and pa-
tients who received interferon vs direct-acting antiviral (DAA) based treatment. No 
differences in risk of all-cause mortality or drug-related death between PCR-negative 
controls and PCR-positive cases were detected. The odds of all-cause mortality was 
12.2 times higher in nonengaging persons compared to treatment engaging cases 
(aOR 12.15, 95% CI 7.03-20.99, P < .001). The odds of a drug-related death were 
5.5 times higher in nonengaging persons compared with treatment engaging cases 
(aOR 5.52, 95% CI 2.67- 11.44, P < .001). No differences in risk of all-cause mortal-
ity or drug-related death between interferon-treated cases and DAA-treated con-
trols were detected. HCV treatment engagement is significantly protective against 
all-cause mortality and drug-related death. This engagement effect is independent 
of treatment regimen, with the introduction of DAA therapies not increasing risk of 
drug-related death, suggesting intensity of HCV therapy provider interaction is not 
an important factor.
K E Y W O R D S
case-control studies, drug-related death, hepatitis C, injecting behaviour, people who inject 
drugs
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1  | INTRODUC TION
Hepatitis C (HCV) is a blood-borne virus and affects up to 1% of 
the Scottish Population.1 Around 90% of those infected with HCV 
acquire the virus through injecting drug use behaviour.2 HCV related 
liver disease is a primary contributor to morbidity and mortality 
among people who inject drugs (PWID).3 HCV is preventable, treat-
able and curable, with research supporting the treatment of active 
injecting drug users for Hepatitis C.4 The efficacy of pan-genotypic 
direct-acting antivirals (DAA) provides an excellent opportunity 
to scale up HCV diagnosis and treatment, ultimately achieving the 
WHO target of HCV elimination by 2030.5,6
There is evidence that HCV care engagement is associated with 
change in behaviours among PWID. Studies have demonstrated the 
positive impact of HCV status notification on reduction in injecting 
behaviour among PWID.7,8 Furthermore, a systematic review high-
lighted the positive impact of HCV treatment on patients’ injecting 
and sharing behaviour.9
The causes of death among PWID are strongly associated 
with active drug use.10 Scotland has observed a twofold increase 
in drug-related deaths between 2008 and 2018, with Tayside ex-
periencing the highest number of drug deaths ever recorded in the 
region in 2018.11,12 It is vital that informed action is urgently under-
taken to reverse this trend.
The introduction of Multidisciplinary Managed Care Networks 
(MCN) in HCV treatment has increased access to services and re-
duced all-cause mortality.13 The associated improvement in access 
into care and HCV treatment may have led to a greater degree of 
engagement with health services and may have had a stabilizing 
effect on drug using behaviour. However, there is concern around 
the potential impact of reduction in intensity of staff contact when 
transitioning from the interferon era to the DAA era of treatment. 
Interferon based treatment required a greater intensity of staff to 
patient engagement due to adverse side effects and long treatment 
duration. Contrastingly, DAA based treatment has minimal side ef-
fects and higher cure rates (in excess of 95%).14 Thus, treatment 
pathways are streamlined and arguably provide less opportunity 
for patients to develop a therapeutic relationship with healthcare 
professionals involved in their care, and therefore reduced opportu-
nities to facilitate change in patients’ drug use behaviour, and lower 
risk of mortality.
The aims were to investigate whether HCV diagnosis and en-
gagement in treatment services reduced all-cause mortality and 
drug-related death, and whether any effect was dependent on 
treatment regimen or intensity of engagement with staff. A series 
of retrospective case-control studies were carried out. Initially, 
comparing PWID with active HCV infection (PCR positive) vs 
PWID who were HCV infected but cured spontaneously (PCR 
negative), to elucidate whether knowledge of HCV infection sta-
tus impacted risk of mortality. Secondly, comparing PCR-positive 
patients who engaged vs did not engage with treatment services 
to assess if outcomes were dependent on engagement. Finally, 
comparing interferon treated patients vs DAA-treated patients, 
exploring the effect of intensity of HCV therapy provider interac-
tion on outcomes.
2  | METHODS
2.1 | Data sources and data linkage
The main data source utilised was the Tayside Hepatitis C Clinical 
Database which records patients tested for Hepatitis C, await-
ing treatment, on treatment, cured and re-infected in Tayside, 
Scotland. Data collected from this database included demo-
graphic information, risk factors, laboratory tests, follow-up and 
treatment outcomes. Patients identified from this database and 
forming our cohort were electronically linked with electronic 
medical records and the Tayside Drug Deaths Database, using 
patients’ Community Health Index (CHI) numbers (unique identi-
fication numbers given to every patient registered with a GP in 
Scotland). Information on patients’ mortality status was obtained 
via electronic medical records. Information regarding confirmed 
drug-related deaths in Tayside was sourced from the Tayside Drug 
Deaths Database which records data on all drug-related deaths 
in Tayside and feeds into national reporting mechanisms through 
NHS Information Services Division and also informs the work of 
the Tayside Drug Death Review Group.
2.2 | Identification of selected cohort
From the Tayside clinical database, a cohort of individuals was identi-
fied whose risk factor for HCV was intravenous drug use. Therefore, 
the definition of PWID in our study is people who have “ever in-
jected” drugs, with no differentiation between recent/active and 
former PWID. Individuals with other risk factors, such as transfusion 
of blood products or maternal transmission were excluded as we 
were specifically investigating the impact of HCV treatment on the 
behaviour of PWID. Individuals with non-Tayside postcodes were 
excluded as drug-related death outcomes would not be registered 
for non-Tayside individuals on the Tayside Drug Deaths Database. 
Individuals co-infected with other blood-borne viruses were ex-
cluded from the selected cohort as these individuals would have 
differing mortality rates and treatment experiences to those only 
infected with HCV. Individuals who were tested or initiated on treat-
ment before January 2008 were excluded as the MCN for HCV care 
in Tayside was introduced in 2008 and this substantially changed the 
care pathways. Lastly, individuals who were tested or initiated treat-
ment after November 2017 were excluded to allow for a minimum of 
one year of follow-up.
For each analysis, cases and controls were defined differently, 
although derived from the same cohort previously described. For 
analysis 1, all individuals who tested HCV antibody positive were 
identified. Cases were defined as PWID with active HCV infection 
(PCR positive), and controls were defined as PWID who were HCV 
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infected but cured spontaneously (PCR negative). For analysis 2, all 
individuals who tested HCV PCR positive were identified. Cases 
were defined as PCR-positive patients who engaged with treatment 
services, and controls were defined as PCR-positive patients who 
did not engage with treatment services. For analysis 3, all individuals 
who were PCR positive and engaged with treatment were identified. 
Cases were defined as pegylated interferon alpha treated patients, 
and controls were defined as DAA-treated patients. For all analyses, 
each case was matched with one control by age group (20-35, 36-51, 
52-67, 68-83, 84+) and sex. Controls from the respective categories 
were randomly selected using an online random number generator.
2.3 | Definition of drug-related death
The definition of a drug-related death is a death where the under-
lying cause is as follows: drug abuse or drug dependence; or drug 
poisoning (intentional or accidental) that involves any substance 
controlled under the Misuse of Drugs Act 1971.11 The National 
Records of Scotland uses the ICD 10 classification system to identify 
cases of drug-related death once a death certificate has been issued.
2.4 | Definitions of predictor variables
2.4.1 | Treatment engagement
“Treatment engagement” was defined as engaging with healthcare 
professionals and commencing treatment. All patients who com-
menced treatment were classified as “treatment engagers”, irrespec-
tive of how many days/weeks of treatment they completed, whether 
they completed their entire course of treatment or not, and the out-
come of their treatment, for example if a sustained viral response 
(SVR) was achieved. Correspondingly, patients who did not com-
mence treatment were classified as “treatment non-engagers”.
2.4.2 | Opioid substitution therapy (OST)
Data were collected on individuals’ OST status around the time of 
testing or treatment. Specifically, for analysis 1 (PCR negative vs 
PCR positive) and analysis 2, (treatment engagers vs nonengagers), 
data were collected on whether individuals were on OST at the time 
of HCV RNA PCR testing, ±6 months. For analysis 3 (interferon vs 
DAA-treated patients), data were collected on whether individuals 
were on OST at the time of treatment commencement, ±6 months.
2.4.3 | Cirrhosis
Data were collected on individuals’ cirrhosis status. Individuals were 
classified as being cirrhotic if their liver stiffness (FibroScan) score 
was 12.5 kPa or above, or their FIB-4 score was 3.25 or above.15
2.4.4 | SVR
Data were collected on individuals’ sustained virologic response 
(SVR) status. SVR was defined as absence of detectable HCV RNA at 
24 weeks after cessation of treatment.
2.5 | Statistical analysis
For analysis 1 (PCR negative vs PCR positive) and analysis 2 (treat-
ment engagers vs nonengagers), follow-up began from first antibody 
positive test. For analysis 3 (interferon vs DAA-treated patients), 
follow-up began from date of treatment commencement. For all 
analyses, survival time was exactly observed or censored at the last 
follow-up date (31st December 2018). All statistical analyses were 
performed using IBM SPSS Statistics 22. Baseline characteristics 
were summarised using descriptive statistics. Inter-correlations be-
tween predictor variables were summarised using Pearson's corre-
lational analyses.
Kaplan-Meier survival analysis was performed to investigate dif-
ferences in the rates of all-cause mortality and drug-related deaths 
between cases and controls. Comparison of survival curves was per-
formed using log-rank tests. Binary logistic regressions were used to 
compare the odds of all-cause mortality and dying of a drug-related 
death among cases with those among controls. We estimated odds 
ratios (ORs) and 95% confidence intervals for all comparisons and 
adjusted all models for the matching variables; age and sex. A num-
ber of other covariates were also included in certain models; SVR, 
OST and cirrhosis.
3  | RESULTS
3.1 | Analysis 1 - PCR positive vs negative
A total of 3431 individuals who tested HCV antibody positive were 
identified. Of these, 386 PCR-negative controls and 918 PCR-
positive cases met the inclusion criteria (see Figure 1) and were ran-
domly matched by age group and sex, leading to 386 PCR-negative 
controls and 386 PCR-positive cases included in the study.
Baseline characteristics of cases and controls are presented in 
Table 1. The majority of cases (96.4%) and controls (96.1%) were 
under the age of 65 years, and male (57.0%).
During the study's follow-up period, there were 135 deaths out 
of 722 individuals who were antibody positive; 72 (53.3%) deaths 
were in PCR-positive cases, and 63 (46.7%) were in PCR-negative 
controls. Of 135 deaths, 63 were classified as drug-related deaths; 
34 (54.0%) were in cases, and 29 (46.0%) were in controls.
For all-cause mortality, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.425, P =.515. No 
difference in risk of all-cause mortality between PCR-negative con-
trols and PCR-positive cases was detected (aOR 1.18, 95% CI 0.80-
1.73, P = .40), after adjustment for age and sex (see Table 2).
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For drug-related deaths, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.291, P =.590. No 
difference in risk of drug-related death between PCR-negative 
controls and PCR-positive cases was detected (aOR 1.19, 95% 
CI 0.71-2.00, P = .512), after adjustment for age and sex (see 
Table 3).
F I G U R E  1   Selection of PCR-positive 
cases and PCR-negative controls based on 
inclusion/exclusion criteria
3431
Individuals tesng HCV anbody
posive 
Potenal Controls = PCR Negave: 
859
Following exclusion of individuals with 
unknown PCR results (N = 11)
Potenal Cases = PCR Posive: 2499
Following exclusion of individuals with 
unknown PCR results (N = 62)
800
Following exclusion of individuals with 
other risk factors e.g. blood products, 
high prevalence country (N = 59)
2288
Following exclusion of individuals with 
other risk factors e.g. blood products, 
high prevalence country (N = 211)
640
Following exclusion of individuals with 
postcodes out with Tayside (N = 160)
2247
Following exclusion of individuals co-
infected with other BBVs (N = 41)
386 PCR Negave controls 
Following exclusion of individuals 
tested before 2008/tested aer 
November 2017 (N = 254)
1999
Following exclusion of individuals with 
postcodes out with Tayside (N = 248)
918 PCR Posive cases
Following exclusion of individuals 
tested before 2008/tested aer 
November 2017 (N = 1081)
Potenal Controls = PCR Negave: 
870
Potenal Cases = PCR Posive: 2561
TA B L E  1   Baseline characteristics of PCR-positive cases and PCR-negative controls (Analysis 1); Treatment Engaging cases and Treatment 
Non-Engaging controls (Analysis 2); and Interferon-treated cases and DAA-treated controls (Analysis 3)
 
Analysis 1 Analysis 2 Analysis 3
Cases (N = 386)
Controls 
(N = 386) Cases (N = 263)
Controls 





41.77 ± 10.9 41.56 ± 10.92 42.86 ± 10.64 42.98 ± 11.17 43.20 ± 9.20 43.80 ± 9.09
Age ≥ 65 years 14 (3.6%) 15 (3.9%) 9 (3.4%) 7 (2.7%) 3 (1.1%) 6 (2.3%)
Male 220 (57.0%) 220 (57.0%) 177 (67.3%) 177 (67.3%) 201 (75.6%) 201 (75.6%)
SVR   187 (71.1%) 122 (46.4%) 234 (88.0%) 211 (79.3%)
OST     197 (74.1%) 184 (69.2%)
Cirrhosis     34 (13.9%) 40 (15.5%)
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3.2 | Analysis 2 - PCR-positive treatment engagers 
vs PCR-positive treatment nonengagers
A total of 2499 individuals who tested HCV PCR positive were iden-
tified. Of these, 267 treatment nonengaging controls and 650 treat-
ment engaging cases met the inclusion criteria (see Appendix S1) 
and were randomly matched by age group and sex, leading to 263 
treatment nonengaging controls and 263 treatment engaging cases 
included in the study (successful matching was not possible for four 
controls).
Baseline characteristics of cases and controls are presented in 
Table 1. The majority of cases (96.6%) and controls (97.3%) were 
under the age of 65 years, and male (67.3%).
During the study's follow-up period, there were 141 deaths out 
of 527 individuals who were PCR positive; 23 (16.3%) deaths were in 
treatment engaging cases, and 118 (83.7%) were in treatment non-
engaging controls. Of 141 deaths, 54 were classified as drug-related 
deaths; 10 (18.5%) were in cases, and 44 (81.5%) were in controls.
For all-cause mortality, the survival distributions for the two 
groups were significantly different, with nonengaging controls at 
a significantly higher risk of all-cause mortality, χ2(2) = 91.395, P = 
<.001 (see Figure 2). The odds of all-cause mortality were 12.2 times 
higher among treatment nonengaging controls, (aOR 12.15, 95% CI 
7.03-20.99, P < .001) compared with treatment engaging cases, after 
adjustment for age, sex and OST (see Table 2).
For drug-related deaths, the survival distributions for the two 
groups were significantly different, with nonengaging controls at a 
significantly higher risk of drug-related death, χ2 (2) = 32.364, P = 
<.001 (see Figure 3). The odds of a drug-related death were 5.5 times 
higher among treatment nonengaging controls, (aOR 5.52, 95% CI 
2.67-11.44, P < .001) compared to treatment engaging cases, after 
adjustment for age, sex and OST (see Table 3).
3.3 | Analysis 3 - Interferon treated vs DAA treated
A total of 1664 PCR-positive individuals who engaged with treat-
ment were identified. Of these, 380 interferon treated cases and 
270 directing acting antiviral-treated controls met the inclusion cri-
teria (see Appendix S1) and were randomly matched by age group 
 B (SE)
95% CI for odds ratio
Lower Odds ratio Upper
Analysis 1
Constant −3.82 (0.42)    
Age 0.05* (0.01) 1.04 1.05 1.07
Sex (Male vs Female) −0.23 (0.20) 0.53 0.79 1.18
PCR status (Negative vs 
Positive)
0.16 (0.20) 0.80 1.18 1.73
R2 (Cox & Snell) = 0.06     
Analysis 2
Constant −6.12* (0.71)    
Age 0.08* (0.01) 1.05 1.08 1.11
Sex (Male vs Female) −0.40 (0.27) 0.40 0.67 1.13




−2.50* (0.28) 7.03 12.15 20.99
R2 (Cox & Snell) = 0.25     
Analysis 3
Constant −3.16* (1.20)    
Age 0.02 (0.02) 0.98 1.02 1.06
Sex (Male vs Female) −0.85 (0.55) 0.15 0.43 1.27
SVR (No vs Yes) −1.17* (0.39) 0.15 0.31 0.66
OST (No vs Yes) 0.44 (0.45) 0.64 1.46 3.71
Cirrhosis (No vs Yes) 0.82 (0.44) 0.95 2.26 5.39
Treatment Regimen (DAA 
vs IFN)
0.37 (0.37) 0.70 1.45 2.98
R2 (Cox & Snell)= 0.04     
*P < .05. 
TA B L E  2   Summary of logistic 
regression analyses for control variables 
(age, sex, SVR, OST and cirrhosis), PCR 
status (Analysis 1), Treatment Engagement 
(Analysis 2) and Treatment Regimen 
(Analysis 3) predicting all-cause mortality
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and sex, leading to 266 interferon-treated cases and 266 directing 
acting antiviral-treated controls included in the study (successful 
matching was not possible for four controls).
Baseline characteristics of cases and controls are presented in 
Table 1. The majority of cases (96.6%) and controls (97.3%) were 
under the age of 65 years, and male (67.3%).
During the study's follow-up period, there were 49 deaths out 
of 532 PCR-positive individuals who engaged with treatment; 35 
(71.4%) deaths were in interferon treated cases, and 14 (28.6%) were 
in DAA-treated controls. Of 49 deaths, 28 were classified as drug-re-
lated deaths; 21 (75%) in cases, and seven (25%) in controls.
Differences in length of follow-up time between cases and con-
trols were controlled for by implementing a limit of a maximum fol-
low-up period of 55 months after treatment commencement. This 
time parameter was decided upon as the first recorded date of 
treatment commencement in the DAA control group was 1st June 
2014, with a 55 months of follow-up until the final day of follow-up 
31st December 2018. Accordingly, any deaths occurring after the 
established maximum follow-up period in the interferon case group 
were not included in the subsequent analysis. Consequently, nine of 
the 35 deaths, and three of the 21 drug-related deaths, occurring in 
cases were not included in the analysis.
For all-cause mortality, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.071, P =.789. No dif-
ference in risk of all-cause mortality between DAA-treated controls 
and interferon-treated cases was detected (aOR 1.45, 95% CI 0.70-
2.98, P = .37), after adjustment for age, sex, SVR, OST and cirrhosis 
(see Table 2). Note, 28 individuals were omitted from the regression 
analysis due to missing data on cirrhosis; eight controls and 20 cases.
For drug-related deaths, the survival distributions for the two 
groups were not significantly different, χ2 (2) = 0.281, P =.596. No dif-
ference in risk of drug-related death between DAA-treated controls and 
interferon-treated cases was detected (aOR 2.06, 95% CI 0.80-5.23, P = 
.13), after adjustment for age, sex, SVR, OST and cirrhosis (see Table 3).
4  | DISCUSSION
The aim of the project was to investigate whether HCV diagno-
sis and engagement with treatment services reduces all-cause 
 B (SE)
95% CI for odds ratio
Lower Odds ratio Upper
Analysis 1
Constant −2.45 (0.57)    
Age 0.00 (0.01) 0.98 1.00 1.03
Sex (Male vs Female) −0.36 (0.28) 0.40 0.70 1.20
PCR status (Negative vs 
Positive)
0.17 (0.26) 0.71 1.19 2.00
R2 (Cox & Snell)= 0.00     
Analysis 2
Constant −3.39* (0.81)    
Age −0.01 (0.02) 0.97 0.97 1.03
Sex (Male vs Female) −0.12 (0.33) 0.47 0.89 1.69




−1.71* (0.37) 2.67 5.52 11.44
R2 (Cox & Snell)= 0.05     
Analysis 3
Constant −3.13* (1.57)    
Age −0.01 (0.03) 0.94 0.99 1.05
Sex (Male vs Female) −0.70 (0.65) 0.14 0.50 1.77
SVR (No vs Yes) −1.38* (0.46) 0.10 0.25 0.62
OST (No vs Yes) 1.45 (0.77) 0.94 4.05 19.35
Cirrhosis (No vs Yes) 0.10 (0.69) 0.29 1.12 4.30
Treatment Regimen (DAA 
vs IFN)
0.72 (0.48) 0.81 2.06 5.23
R2 (Cox & Snell)= 0.03     
*P < .05. 
TA B L E  3   Summary of logistic 
regression analyses for control variables 
(age, sex, SVR, OST, and cirrhosis), PCR 
status (Analysis 1), Treatment Engagement 
(Analysis 2) and Treatment Regimen 
(Analysis 3) predicting drug-related death
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mortality and drug-related death, and whether any effect is de-
pendent on treatment regimen and intensity of engagement with 
HCV treatment service staff. A series of retrospective case-con-
trol studies were performed. The first compared PWID with ac-
tive HCV infection (PCR positive) vs PWID who had been HCV 
infected but cured spontaneously (PCR negative) to answer the 
question does knowledge of HCV infection status change risk of 
death. The only difference between cases and controls was the 
random biological event of spontaneous HCV cure; the two co-
horts can be presumed to have behaved in the same way up to 
the point of being told their HCV status. Our results suggest that 
awareness of HCV infection status makes no difference to mor-
tality, either all cause or drug related.
PWID with a diagnosis of HCV have an increased risk of mortal-
ity compared with noninfected PWID.16 Recent studies have shown 
that awareness of HCV status can be protective, with a reduction 
in injecting behaviour seen in those who have been notified of their 
status.7,8 It has been posited that this behavioural change may occur 
as a result of treatment engagement by some patients rather than 
due to knowledge of HCV status itself.
F I G U R E  2   Kaplan-Meier survival 
curve for time from first antibody positive 
test to all-cause mortality comparing 
treatment engaging cases and treatment 
nonengaging controls
F I G U R E  3   Kaplan-Meier survival 
curve for time from first antibody positive 
test to drug-related death comparing 
treatment engaging cases and treatment 
nonengaging controls
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In the second analysis, we looked at PCR-positive patients 
who engaged vs did not engage with treatment services to explore 
whether self-selecting engagement behaviour accounts for the per-
ceived difference in mortality. Our findings provide evidence that 
HCV treatment engagement is a significant protective factor against 
both all-cause mortality and drug-related death among PWID, with 
nonengaging PCR-positive individuals having 12 times higher odds 
of all-cause mortality and 5 times higher odds of drug-related death, 
in comparison to PCR-positive treatment engaging persons. These 
findings confirm previous research that engaging in Hepatitis C 
treatment leads to a reduction in all-cause mortality.13 It is import-
ant to note that our cohort was selected from a population that has 
a high testing and diagnosis rate, nearly reaching WHO 2030 targets 
with a large proportion being treated to date, so there is minimal 
selection bias in our cohorts. This highlights the need for greater col-
laboration between specialist substance misuse services and HCV 
treatment services to operate in an integrated structure to tackle the 
observed rising trends in drug-related deaths. It is imperative to en-
sure that all services are equipped with adequate levels of resources 
and staffing to assess, manage and treat both patients’ Hepatitis C 
and problematic drug use successfully. Furthermore, engagement in 
HCV care may provide an opportune time to implement targeted 
interventions to reduce injecting behaviours and promote further 
harm reduction measures.
The final analysis attempted to explore further if there was any 
effect of treatment engagement by comparing the outcomes of in-
tensive interaction with health care in interferon treated patients 
vs DAA-treated patients, who have much shorter and less intense 
engagement. The result clearly shows no difference, suggesting that 
the benefits of treatment engagement are associated with the act 
of engaging with treatment rather than the treatment regime itself. 
It could be argued that patients engaging with HCV treatment ser-
vices are self-selecting individuals who are more willing to engage 
with services in general, and that we have observed a generalised 
engagement effect, rather than a specific HCV treatment effect. 
Additionally, it is not clear if nonengaging behaviour is amendable 
to change or improved prognosis. Future research should focus on 
promotion of HCV care and engagement strategies, highlighting the 
psychological, social and physical health benefits of achieving a cure, 
as well as treatment options.17 This finding highlights the importance 
of inclusive accessibility of HCV treatment for PWID.
This finding also has significant implications for addressing on-
going concern around the change in intensity of staff contact when 
transitioning from the interferon era to the DAA era of treatment. 
In addition, it is important to consider that DAA-treated patients 
are arguably more unstable than interferon treated patients as 
many would have been deemed to be unsuitable for interferon 
therapy due to associated adverse side effects. Indeed, it has 
been hypothesised that DAA-treated patients might have worse 
outcomes than interferon treated patients given the less intensive 
support during therapy. Thus, the fact that we observed no differ-
ence in risk of all-cause mortality or drug-related deaths between 
the two groups is evidence that intensity of staff engagement is 
not an important protective factor. Consequently, current treat-
ment practice does not need to implement an increase in intensity 
of staff contact.
4.1 | Limitations
The predominant limitation of the current study was the retrospec-
tive study design, with substantial limitations in quality of available 
data. Data on a number of meaningful variables were not available. 
For instance, OST data were not attainable for PCR-negative indi-
viduals and therefore could not be included as a predictor variable 
in the regression model in analysis 1. Moreover, available OST data 
indicated whether individuals were on OST at the time of diagnosis, 
but not whether they were on OST at the time of their death, which 
could have given more insights. Data on history of nonfatal over-
doses would also have been advantageous, as previous research has 
demonstrated that nonfatal overdose is classified as a risk factor for 
ensuing fatal overdose in PWID.18 Other unattainable data which 
could have been beneficial were injecting history, injecting status, 
change in injecting behaviours and other significant comorbidities.
Furthermore, data on unmeasured potential confounding vari-
ables which may explain the association between engagement and 
decreased risk of mortality is lacking, with further research needed 
to elucidate the complex reasons that lead to nonengagement.
Another limitation to the current study is the lack of differenti-
ation of individuals in analysis 2 (treatment engagers vs nonengag-
ers). Specifically, engagers were not differentiated by a more specific 
measurement of treatment engagement, for example how many 
weeks of treatment they completed and/or whether they completed 
their full course of treatment. Equivalently, nonengagers were not 
differentiated by the reason for their nonengagement. For instance, 
a minority of patients may have not started treatment due to con-
cerns around treatment contra-indications or age. This is particularly 
relevant for patients treated in the interferon treatment era due to 
higher incidence of associated adverse side effects compared with 
DAA based treatment regimens. Arguably such differentiation may 
provide greater insight into the impact of treatment engagement on 
subsequent risk of death, and whether, for example, completion of 
treatment potentiates the engagement effect.
5  | CONCLUSIONS
In conclusion, a series of case-control studies were conducted to in-
vestigate the impact of HCV diagnosis and engagement in treatment 
services on risk of all-cause mortality and drug-related death among 
PWID. No difference in risk of all-cause mortality or drug-related death 
was observed between PWID with active HCV infection (PCR positive) 
and HCV infected but cured spontaneously (PCR negative). HCV treat-
ment engagement is significantly protective against all-cause mortality 
and drug-related death, with nonengaging PCR-positive individuals 12 
times higher odds of all-cause mortality and five times higher odds of 
584  |     CAVEN Et Al.
drug-related death, in comparison to PCR-positive treatment engaging 
persons. This engagement effect is independent of treatment regimen, 
with no difference in risk of all-cause mortality or drug-related death 
between interferon treated patients and DAA-treated patients, sug-
gesting intensity of engagement with staff is not an important factor. 
These findings provide further evidence of the importance of HCV di-
agnosis and treatment engagement among PWID, reducing their risk of 
mortality, beyond liver-related outcomes.
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